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Résumé 
Les antipsychotiques de deuxième génération (ADG) sont de plus en plus employés dans le 
traitement de troubles psychiatriques. Selon de nombreuses observations cliniques, les 
effets secondaires reliés à la prise d’ADG diffèrent chez les patients atteints de 
schizophrénie (SCZ) et de maladies affectives (MA) éprouvent divers. Ainsi, il s’avère 
nécessaire d’étudier la fréquence et l'intensité des effets secondaires induits par les ADG 
qui pourraient différer selon  le diagnostic. Pour ce faire, nous avons effectué une revue 
systématique de la littérature afin d’identifier l’ensemble des études rapportant les effets 
secondaires de cinq ADG (aripiprazole, olanzapine, quétiapine, rispéridone et ziprasidone) 
dans le traitement de la schizophrénie ou des maladies affectives.  Les effets secondaires 
métaboliques et extrapyramidaux ont été recueillis séparément pour les deux groupes de 
patients, puis ont été combinés dans une méta-analyse. Des méta-régressions ainsi que des 
sous-analyses ont également été effectuées dans le but de regarder l’effet de différents 
modérateurs (i.e. âge, genre, et dose). Dans la présente méta-analyse, 107 études ont été 
inclues. Les résultats montrent que le traitement avec l’olanzapine a occasionné une plus 
importante prise de poids chez les patients SCZ comparativement aux patients MA.  De 
plus, le traitement à la quétiapine a amené  une hausse significative du taux de LDL et de 
cholestérol total dans le groupe SCZ par rapport au groupe MA. Selon nos résultats, les 
symptômes extrapyramidaux étaient plus fréquents dans le groupe MA, excepté pour le 
traitement à l'olanzapine qui a induit davantage de ces symptômes chez les patients SCZ. 
Également, nos résultats suggèrent que les patients SCZ seraient plus vulnérables à certains 
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effets métaboliques induits par les ADG dû à une possible susceptibilité génétique ou à la 
présence de facteurs de risque associés au style de vie. D'autre part, les patients MA en 
comparaison aux SCZ étaient plus enclins à souffrir de troubles du mouvement induits par 
les ADG. Bref, les ADG semblent exacerber certains types d’effets secondaires tout 
dépendant de la maladie dans laquelle on les utilise. 
Mots-clés : Antipsychotiques de deuxième génération, Maladies affectives, Schizophrénie, 
Syndrome métabolique, Symptômes extrapyramidaux, Méta-analyse. 
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Abstract 
Second generation antipsychotics (SGAs) are extensively prescribed for psychiatric 
disorders. Based on clinical observations, schizophrenia (SCZ) and affective disorders 
(AD) patients experience different SGAs side effects. The expanded use of SGAs in 
psychiatry suggests a need to investigate whether there is a difference in the incidence and 
severity of side-effects related to diagnosis. A comprehensive literature search was 
conducted to identify studies reporting side effects of five SGAs (aripiprazole, olanzapine, 
quetiapine, risperidone and ziprasidone) in the treatment of SCZ or AD. The metabolic and 
extrapyramidal side effects were collected separately for each group, and then were 
combined in a meta-analysis. Meta-regression and sub-analyses were also performed to 
investigate the role of different moderators (e.g., age, dose and gender). One hundred and 
seven studies were included in the analysis. Olanzapine induced a body weight gain 
significantly higher in SCZ patients than in AD patients. In addition, quetiapine treatment 
led to significantly higher LDL and total cholesterol mean change in the SCZ group relative 
to the AD group. Based on our results, the incidence of extrapyramidal side effects was 
more frequent in the AD group, except for olanzapine that caused more parkinsonism in 
SCZ patients. Our results suggest that SCZ patients may be more vulnerable to some SGA-
induced metabolic disturbances, in which lifestyle risk factors and a possible inherent 
genetic vulnerability may play a role. Most of the studied SGAs caused more movement 
disorders in AD patients than in schizophrenics. It might be that an antipsychotic induces 
severity of side effect according to the phenotype.  
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1.1. Schizophrenia  
1.1.1. Clinical description  
Schizophrenia is a severe, chronic and debilitating psychiatric disorder. Ranking among the 
ten most frequent causes of disability in developed countries (Rossler et al., 2005), it affects 
around 0.3% to 0.7% of the world’s population at some point in their life (van Os and 
Kapur, 2009). Schizophrenia is characterized by disordered thinking, hallucinations, 
delusions, bizarre behaviour and inappropriate emotional responses. The disorder can 
appear at any age, although symptoms most commonly appear in late adolescence or early 
adulthood; however, cognitive disturbances are often evident earlier (Carpenter and 
Buchanan, 1994, Tamminga and Holcomb, 2005). Based on epidemiological studies, men 
and women are affected equally often, but women are generally diagnosed at a slightly later 
age; in addition, some gender differences in the course of this disorder exist (Brown and 
Estoup, 2005, Meyer and Quenzer, 2005). Schizophrenia is estimated to be the seventh 
most costly and disabling disease affecting the age group between 20 and 45 years old, 
because of the high frequency of hospitalizations, the need for psychosocial services and 
lost productivity (Arguello et al., 2010, Goeree et al., 2005, Ibrahim and Tamminga, 2011, 
McIntyre et al., 2010). 
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1.1.2. Symptoms 
According to the definition in the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) (APA, 1994), in order to make the diagnosis of schizophrenia, 
continuous signs of illness, which may include symptoms from the prodromal and residual 
phases of the illness that are not psychotic, must be evident for at least 6 months, 
accompanied by a decrease in functioning from the premorbid level. Schizophrenia is 
diagnosed in patients who have two or more of the following symptoms for more than one 
month (during the last 6 months): hallucinations, disorganized speech and behaviour, 
delusions, affective flattening, alogia and avolition. In addition, patients’ social functioning 
must have deteriorated (Smith et al., 2010).  
 Individuals with schizophrenia experience different kinds of symptoms: positive, 
negative and cognitive. Positive symptoms include delusions (beliefs that have no basis in 
reality); hallucinations (auditory or visual), for example hearing voices that are not there; or 
communicating in a way that is difficult to understand, such as disorganized speech and 
behaviour. For many schizophrenia patients, emotions are absent or inappropriate to the 
situation; speech and thoughts are also disrupted and may shift from one subject to a totally 
unrelated subject.  
 Negative symptoms are characterized by a decline in regular functioning, including 
reduced speech (alogia), loss of motivation (avolition), loss of pleasure in normally 
pleasurable activities (anhedonia), inhibition of facial expressions and decline in emotional 
responsiveness (flattened affect).  
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 Cognitive symptoms relate to thought processes and include difficulty with planning 
and structuring activities, learning and memory problems, difficulty maintaining attention, 
loss of insight and impaired judgment (Meyer and Quenzer, 2005, Smith et al., 2010). 
1.1.3. Etiology and pathophysiology  
The precise cause of schizophrenia is widely debated. Multiple factors, including genetic 
susceptibility variations, viruses, toxins, birth injuries, neurological disorders and 
psychological experiences, among others, have been argued to be possible factors leading 
to schizophrenia.  
 It is now generally recognized the neurotransmitter hypotheses (dopamine, glutamate 
and others) are the consequence of previous neurodevelopmental alterations that occurred 
in utero or around birth. The neurodevelopmental abnormalities remain relatively silent 
during brain maturation because of the extraordinary plastic capacity of the neural tissue. 
But, at adulthood, these abnormalities (principally related to synaptic function) generate 
brain neurochemical imbalances, which are associated with symptoms expression (Lewis 
and Levitt, 2002). The most widely accepted hypotheses to explain the etiology and 
pathophysiology of schizophrenia disorders are discussed below, based on work by Meyer 
and Quenzer (2005), Miyamoto et al. (2002) and Smith et al. (2010). 
1.1.3.1. Genetic and environmental factors  
The importance of heredity is demonstrated by linkage studies, genetic epidemiological 
investigations, DNA microarrays and twin studies. Research in molecular genetics is 
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currently focusing on the identification of the specific genes that predict susceptibility to 
schizophrenia. Multiple gene abnormalities may be responsible for a given variation in the 
appearance and intensity of symptoms between two individuals. Drug use, endocrine 
diseases, malnutrition, stress and brain hypoxia during pregnancy and delivery may 
increase the probability of schizophrenia (Tsuang, 2000). 
1.1.3.2. Neurodevelopmental hypothesis 
Another hypothesis concerning the pathology of schizophrenia concerns abnormal brain 
structure. Brain abnormalities and cell disorganization found in schizophrenia patients 
include enlarged ventricles, decreased hippocampal volume, decreased grey matter volume, 
decreased activity in the frontal lobe, failure of the prefrontal cortex and asymmetrical 
hemispheres (Rubesa et al., 2011).   
1.1.3.3. Dopaminergic hypothesis 
One hypothesis that has gained a good deal of support is that dopamine levels are abnormal 
in schizophrenia patients. After more than three decades, this assumption is still dominant 
in the pathophysiology of schizophrenia and is believed to explain the genesis of positive 
symptoms in particular. The concepts underlying this hypothesis came from the seminal 
work of Carlsson and Lindqvist (1963) describing the presence of dopamine in the brain 
and the effects of neuroleptics on monoaminergic indices. The dopaminergic hypothesis of 
schizophrenia proposes that hyperactive dopamine transmission in mesolimbic 
dopaminergic neurons is associated with positive symptoms episodes. This has been 
confirmed by Laruelle in schizophrenia patients using brain imaging (Laruelle et al., 1996). 
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In addition, increased numbers of D2 receptors in the nucleus accumbens, basal ganglia and 
substantia nigra of post-mortem schizophrenic brains confirm the involvement of dopamine 
in developing this disorder. The work of Glenthoj et al. (2006) showed a positive 
correlation between the activity of D2/D3 dopamine receptors in the frontal cortex and 
positive psychotic symptoms.  
 The classical dopamine hypothesis has received further support from other studies 
(Creese et al., 1976, Levin et al., 1989, Nakajima and Baker, 1989, Seeman and Lee, 1975) 
which found a positive correlation between clinical doses of antipsychotic drugs and their 
potency in blocking D2 dopamine receptors. Atypical antipsychotics are therapeutic agents 
that increase dopamine in mesocortical areas and simultaneously decrease the activity of 
dopamine in the mesolimbic dopamine pathway (Takahashi et al., 2006). Further 
investigations showed that, after exposure to certain psychostimulants, such as 
amphetamine and cocaine, the increase in dopamine release is greater in schizophrenia 
patients than in healthy volunteers (Breier et al., 1997, Laruelle and Abi-Dargham, 1999). 
In addition, psychostimulants increase dopaminergic neurotransmission and induce 
psychosis similar to schizophrenia in some healthy subjects (Depatie and Lal, 
2001). Psychostimulants also exacerbate psychosis in some schizophrenia patients 
(Harrison et al., 2008, Zhornitsky et al., 2011). 
1.1.3.4. Glutamatergic hypothesis 
Glutamate is the most widely distributed transmitter in the central nervous system and is 
known to interact with the central dopaminergic system in many ways. Glutamate acts via 
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large families of receptors: ionotropic (NMDA (N-methyl-D-aspartate), AMPA (α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) and kainite) and metabotropic 
receptors (mGluRs). The idea of a glutamatergic abnormality in schizophrenia was first 
suggested by Kim et al. (1980), based on their findings of low cerebrospinal fluid glutamate 
levels in schizophrenia patients. Grace (1991) proposed a glutamate-dopamine model, 
which emphasizes that cortical glutamate can regulate sub-cortical release of dopamine 
neurotransmitter. Therefore, the loss of glutamate inputs to the subcortical dopamine centre 
should lead to excess dopamine activity and produce the positive symptoms of 
schizophrenia.  
 Antagonists of glutamate receptors such as ketamine and PCP (phencyclidine) can 
produce positive, negative and cognitive symptoms of schizophrenia in healthy volunteers 
(Grace, 1991, Javitt and Zukin, 1991, Lahti et al., 1995, Polimeni and Reiss, 2002). This 
glutamatergic theory is supported by post-mortem studies showing that levels of glutamate 
and NMDA receptors have changed in schizophrenia patients (Konradi and Heckers, 2003, 
Ulas and Cotman, 1993). 
 Hypofunction of NMDA receptors in schizophrenia has been indicated based on 
various clinical, neuropathological and genetic findings (Bennett and Gronier, 2005, 
Conley et al., 2005, Scarr et al., 2005). 
1.1.3.5. Role of other neurotransmitters 
Further studies discovered that other neurotransmitters, such as serotonin and acetylcholine, 
may also be involved in the pathophysiology of schizophrenia. An increased number of 5-
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HT2A and 5-HT1A cortical receptors has been observed in the brains of schizophrenia 
patients. The polymorphism of the 5-HT2A receptor gene has also been verified; this may 
indicate insufficient 5-HT2A-receptor-mediated activation of the prefrontal cortex 
(Aghajanian and Marek, 2000). Post-mortem and neuroimaging studies in schizophrenia 
patients have shown a reduced number of M1 and M4 muscarinic receptors in crucial loci, 
such as the caudate nucleus, hippocampus, putamen and prefrontal cortex, as well as the 
anterior and posterior cingulate cortex (Raedler et al., 2003). 
 The pathophysiology of schizophrenia is complex; no one model seems to fit perfectly, 
and schizophrenia researchers continue to strive to learn more. Most experts believe that 
schizophrenia is the result of a combination of genetic and environmental factors, as well as 
psychological and neurobiological abnormalities. 
1.1.4. Diagnosis 
The diagnosis of schizophrenia is not a simple matter, even though the symptoms described 
above seem relatively easy to distinguish. At present, due to a lack of clear biological 
markers for the disorder, the only diagnostic approach is based on symptoms. However, the 
symptoms vary from one individual to another; they also change over time, which can lead 
to a change in diagnosis. The lack of diagnostic tests and biological markers to define the 
illness’s onset and follow its progression makes treatments primarily symptomatic (Ibrahim 
and Tamminga, 2011, Meyer and Quenzer, 2005). Schizophrenia has been further sub-
classified, according to the most significant characteristics present in each patient. 
Consequently, each person may be diagnosed with different schizophrenia sub-types during 
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the course of the illness. Based on the DSM-IV-TR, these sub-classes include catatonic, 
paranoid, disorganized, undifferentiated and residual types (APA, 2000). 
1.1.5. Pharmacological treatments 
The aims of the pharmacological treatment of schizophrenia include the improvement of 
symptoms and quality of life, the rehabilitation of patients, and the prevention of relapse 
and re-hospitalization. 
 Because of the nature of schizophrenia (which appears to be a combination of thought, 
mood and anxiety disorders), the medical management of this disorder often requires a 
combination of antipsychotic, antidepressant and anxiolytic medications. Antipsychotic 
medications help to normalize the biochemical imbalances that occur in schizophrenia. 
Many medications are included in the antipsychotic group, and they are commonly divided 
into two major classes: typical (or first-generation) antipsychotics and atypical (or second-
generation) antipsychotics.   
1.1.5.1. First-generation antipsychotics (FGAs) 
The first-generation or typical antipsychotic medications such as chlorpromazine and 
haloperidol have been available for schizophrenia treatment since the 1950s. Conventional 
antipsychotics, previously named neuroleptics, serve as antagonists for major 
neurotransmitters such as the dopamine receptor family (D2, D3 and D4), muscarinic 
cholinergic receptors (M1), -adrenergic receptors ( and ) and histaminic receptors 
(H1) (Wilkaitis et al., 2006). The different antipsychotic potencies of FGAs are related to 
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their affinity for blocking D2 dopamine receptors or inhibiting dopamine release (Smith et 
al., 2010). Many typical antipsychotics are available in both oral and intramuscular 
formulations. They are effective in treating positive symptoms including hallucination and 
delusion. However, these agents are less efficacious for negative symptoms including 
anhedonia, avolition and social withdrawal, as well as cognitive symptoms such as memory 
deficit. The majority of FGAs are metabolized by cytochrome P450 2D6 (CYP2D6) and 
CYP3A4. Typical antipsychotics are used in schizophrenia, schizoaffective disorder, 
affective disorder, Tourette’s syndrome, nausea, emesis and hiccups. Shortly after 
chlorpromazine started to be used extensively, clinicians observed parkinsonian signs and 
symptoms in some treated patients. Neuromuscular central nervous system side effects, 
such as extrapyramidal symptoms (EPS) and tardive dyskinesia, are common during FGA 
treatment and happen due to D2 antagonism in the nigrostriatal dopaminergic pathway 
(Wilkaitis et al., 2006). EPS are most frequent with high-potency FGAs, such as 
haloperidol. These movement disorders cause lack of compliance and relapse. The 
antagonist action of FGAs on dopaminergic, histaminic, adrenergic and muscarinic 
receptors induces cognitive deficits such as sedation, dizziness and disturbed concentration, 
and many other undesirable side effects such as drowsiness, weight gain, QTc prolongation, 
dry mouth, ocular side effects and hyperprolactinemia (Wilkaitis et al., 2006). 
1.1.5.2. Second-generation antipsychotics (SGAs)  
In contrast to first generation antipsychotic, second-generation antipsychotics (also called 
atypical antipsychotics) are agents that have been available only since the early 1990s. 
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Clozapine the first drug approved in this class introduced in 1971 and marketed in the 
United States of America in 1990. During the 1990s, olanzapine, risperidone and quetiapine 
were introduced, followed by ziprasidone and aripiprazole in the early 2000s (Hasnain et 
al., 2009). According to the treatment guidelines, SGAs include drugs such as amisulpride, 
aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and 
zotepine. In addition to dopamine D2 receptor blocking, SGAs show broad-spectrum 
binding to other receptors, including dopamine (D1, D3, D4), norepinephrine (α1 and α2), 
serotonin (5-HT1A, 2A, 2C, 3, 6, 7), muscarinic cholinergic (M1) and histamine receptors (H1) 
(Stahl, 2008). 
 SGAs are characterized as reducing schizophrenic symptoms, while having a lower 
tendency to cause EPS and tardive dyskinesia than FGAs. They also show a low potency to 
induce hyperprolactinemia (except for risperidone and amisulpride) (Svestka et al., 2007). 
Over the past decade, they have become the first-line treatment for schizophrenia due to 
this more favourable safety profile than FGAs. Furthermore, SGAs raise hopes of superior 
effects in a number of areas, including improving negative symptoms, compliance, 
cognitive functioning, movement disorders, depression and quality of life (Leucht et al., 
2009a, Leucht et al., 2003a, Rosenheck et al., 2003). Some studies have suggested that 
some SGAs (clozapine, olanzapine, amisulpride and risperidone) are more efficacious than 
FGAs (Davis et al., 2003, Leucht et al., 2009b, Leucht et al., 1999, Leucht et al., 2003a). 
Nevertheless, the lack of significant superiority in efficacy observed in large trials has 
indicated that the first and second generation antipsychotics are generally similar in terms 
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of efficacy (Geddes et al., 2000, Jones et al., 2006, Lieberman et al., 2005, Wahlbeck et al., 
2001). Clinicians and researches have different opinions about the comparative 
effectiveness of first- and second-generation antipsychotics (Leucht et al., 1999, Lieberman 
et al., 2003). 
 Two reasons have been proposed to explain the differences between typical and 
atypical antipsychotics. First, atypical antipsychotics have a lower affinity for the 
dopaminergic receptors and a high degree of occupancy of the 5-HT2A receptors (Meltzer et 
al., 1989). Meltzer et al. (1989) provided evidence that atypical antipsychotics combine 
5HT2A/D2 antagonistic actions with greater relative potency at the 5-HT2A receptor. Second, 
atypical antipsychotics have the ability to rapidly dissociate from D2 receptors (Kapur and 
Seeman, 2000); therefore, SGAs help patients by transiently occupying D2 receptors, and 
then they rapidly dissociate to allow normal dopamine neurotransmission. A lower affinity, 
a faster dissociation, and a higher off-rate for the D2 receptors have been proposed as the 
mechanisms of SGAs (Stahl, 2008). 
It is important to mention that problems associated with specific atypical 
antipsychotic treatments include metabolic effects such as weight gain, lipid dysregulation, 
hyperglycemia and cardiovascular abnormalities (American Diabetes Association, 2004, 
Correll et al., 2009). Weight gain and metabolic issues are even greater concerns in the 
treatment of children and adolescents (Maayan and Correll, 2011).  
 In section 1.3, we will discuss the mechanism and safety profiles of SGAs in more 
detail. 
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1.2. Affective disorders 
1.2.1. Clinical description 
Mood or affective disorders represent a large and heterogeneous group of clinical 
syndromes and, along with anxiety disorders, they are the most common psychiatric 
problems. The DSM-IV (APA, 1994) describes two general classes of affective disorders: 
major depression and bipolar disorder. Major depression (unipolar depressive disorder) is 
characterized by severe depression and by recurring episodes of negative thinking and 
anhedonia that are also reflected in behaviour. Bipolar disorder (historically known as 
manic-depressive disorder) is characterized by mood alteration from depression to mania 
over time. Both of these general classes of affective disorders are described as excessive 
and inappropriate exaggerations of moods. As mentioned above, affective disorders are 
among the most common forms of mental illnesses. The estimated incidence of depression 
varies widely; however, some studies have reported that 15% to 20% of the general 
population experiences depression at one point during their lifetime. Moreover, according 
to epidemiological studies, women are twice as likely to develop certain mood disorders, 
such as major depression. Based on the DSM-IV diagnostic criteria (APA, 1994), the 
prevalence of bipolar disorder is approximately 0.5% to 1% in the general population. 
Equal numbers of men and women are diagnosed with bipolar disorder (Yatham and 
Kusumakar, 2009, Yatham and Malhi, 2011). 
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1.2.2. Symptoms  
During depressive episodes of bipolar disorder, patients feel the essential elements of 
depression including helplessness, hopelessness, fatigue and lack of interest and energy to 
do even the fun activities they normally enjoy. In the manic phase, patients are full of 
energy and more talkative than usual, and they feel incapable of making mistakes (Yatham 
and Kusumakar, 2009, Yatham and Malhi, 2011). 
1.2.3. Etiology 
Heredity and environmental stress as well as physiological factors and altered biological 
rhythms such as cortisol secretion and neurotransmitter levels are known risk factors for 
affective disorders. Serotonin, dopamine and norepinephrine are the most important 
neurotransmitters related to mood disorders. Family studies, linkage studies and twin 
studies have demonstrated the role of genetics in the etiology of both major depression and 
bipolar disorder. Family studies and neurobiological studies have found a strong 
association between anxiety and depression (Yatham and Kusumakar, 2009, Yatham and 
Malhi, 2011). 
1.2.4. Diagnosis  
A mood disorder is more than the occasional blues or depressive feelings that most people 
feel sometimes. A mood disorder is actually a manifestation of a mental illness and needs to 
be correctly diagnosed and treated. Proper diagnosis of clinical depression is the key to its 
successful treatment. Misdiagnosis or delayed diagnosis has negative consequences such as 
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inappropriate treatment, increased suicide rate and decreased quality of life for patients. 
Laboratory tests cannot be used to diagnose affective disorders. All diagnostic tests for 
mood disorders contain a questionnaire that is able to determine whether or not an 
individual has a mood disorder (Newman, 2002 , Yatham and Kusumakar, 2009). 
1.2.5. Pharmacological treatments 
Antidepressants such as tricyclic antidepressants (TCAs), monoamine oxidase inhibitors 
(MAOIs), selective serotonin reuptake inhibitors (SSRIs), anxiolytic medications, mood-
stabilizing drugs (e.g., lithium carbonate) and some SGAs (e.g., olanzapine and quetiapine) 
have been successfully used for the treatment of affective disorders. Nowadays, the use of 
atypical antipsychotics in affective disorders is increasing. SGAs are effective at reducing 
agitation and aggressive behaviour (Citrome, 2002, Zeller and Wilson, 2011). They also 
improve psychotic signs and behaviour disorders related to bipolar disorder and unipolar 
depression (Vieta, 2004). The U.S. Food and Drug Administration (FDA) has approved 
aripiprazole, olanzapine, quetiapine, risperidone and ziprasidone for the treatment of manic 
and mixed bipolar episodes (Tohen and Vieta, 2009). Two large international, randomized, 
double-blind, placebo-controlled studies reported that quetiapine monotherapy is effective 
in bipolar mania (Bowden et al., 2005, McIntyre et al., 2005). In addition, quetiapine has 
FDA approval for the treatment of acute bipolar depression. Recent studies have revealed 
that some SGAs may have antidepressant properties (Calabrese et al., 2005, Tohen et al., 
2003). Monotherapy and adjunctive therapy with SGAs showed greater efficacy in the 
  
 
16
treatment of major depressive disorders than placebos (Chen et al., 2011, Yatham and 
Malhi, 2011). 
1.3. Atypical antipsychotics 
As mentioned above, we will discuss the pharmacological and safety properties of the five 
most commonly used SGAs. A brief description of each medication considered in our meta-
analysis is presented here. Because of the chronic nature of the disorder, most individuals 
diagnosed with schizophrenia require continuous and comprehensive care; therefore, 
pharmacotherapy with antipsychotic medications is an essential component of a treatment 
plan for the majority of patients with this illness. 
1.3.1. Pharmacological properties of atypical antipsychotics 
1.3.1.1. Olanzapine 
Olanzapine is a thienobenzodiazepine derivative and is chemically similar to clozapine. 
Olanzapine has a high affinity for serotonin (5-HT2A, 5-HT2C and 5-HT6), dopamine (D2-4), 
histamine (H1) and 1-adrenergic receptors. It also has a moderate affinity for muscarinic 
receptors (M1-5), 5-HT3,7, D1,5 and 2-adrenergic receptors. This atypical antipsychotic 
binds approximately twice as much to 5-HT2A as to D2 receptors (Bhana and Perry, 2001). 
Olanzapine treatment is currently available in oral formulations (tablets and orally 
disintegrating tablets) and intramuscular preparations. Olanzapine is well absorbed after 
oral administration; mean half-life is 36 hours and the compound is approximately 93% 
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protein-bound. It is primarily metabolized by the hepatic enzymes CYP1A2 and CYP2D6 
(Deeks and Keating, 2008, Schulz  et al., 2006). It is prescribed for acute mania (Tohen et 
al., 2000, Tohen et al., 1999), bipolar depression (Keck, 2005), schizophrenia and bipolar 
mania (Bhana and Perry, 2001, Frampton, 2010). Dystonic reactions and parkinsonism are 
uncommon and olanzapine produces fewer treatment-emergent neurological adverse events 
than haloperidol. Based on olanzapine’s higher affinity for 5-HT2A than D2 receptors, a 
lower risk of EPS with clinical doses is predictable (Deeks and Keating, 2008). The main 
problems regarding the safety of this antipsychotic are weight gain and metabolic 
disturbances including hyperlipidemia and hyperglycemia that can lead to other 
complications such as diabetes mellitus, cardiovascular diseases (CVD) and metabolic 
syndrome (Deeks and Keating, 2008, Meyer and Quenzer, 2005, Parsons et al., 2009, 
Sechter et al., 2002). 
1.3.1.2. Quetiapine 
Quetiapine is a dibenzothiazine derivative and has a pharmacological profile similar to that 
of clozapine but with an improved safety profile regarding metabolic side effects. 
Quetiapine has an antagonist affinity for D1 and D2 receptors, serotonin 5-HT2A, -
adrenergic and histamine receptors. It is also a partial agonist for 5-HT1A receptors. 
Norquetiapine, an active metabolite of quetiapine, is a potent inhibitor of norepinephrine 
transporter, which may explain quetiapine’s antidepressant effects (Cutler et al., 2009, 
Garakani et al., 2008). Its mean half-life is approximately six hours, which suggests twice-
daily dosing. However, in some cases, once-daily dosing is an effective option to improve 
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medication adherence. Quetiapine is approximately 83% protein-bound. It is metabolized 
primarily by CYP3A4 and to a much lesser extent by CYP2D6 (Meulien et al., 2010, 
Potkin et al., 2005, Printz and Lieberman, 2006a). 
Quetiapine is an FDA-approved atypical antipsychotic for treatment of schizophrenia, 
bipolar disorder, major depression and anxiety disorders. With its great range of potential 
uses, quetiapine is sometimes known as the aspirin of psychiatry (Stip, 2009). It has been 
shown to be effective against a broad range of schizophrenia symptoms, including positive, 
negative, cognitive and affective symptoms (Arvanitis and Miller, 1997, Emsley and 
Oosthuizen, 2003, Purdon et al., 2001, Sajatovic et al., 2002, Sax et al., 1998, Small et al., 
1997, Velligan et al., 2002). 
 The most frequently reported adverse events are headache, dizziness and somnolence. 
Due to its low D2 affinity compared to 5-HT1A receptors, quetiapine, even at higher doses, 
is less likely to cause EPS than other antipsychotics used for schizophrenia (Arvanitis and 
Miller, 1997, Miller et al., 1998). For this reason, this medication is often preferred for 
treating psychosis or agitation in patients with Parkinson disease (Friedman, 2003). 
Nevertheless, quetiapine, like all atypical antipsychotics, bears a small yet significant risk 
of tardive dyskinesia. In the short term, the most common adverse event is somnolence, 
which generally subsides over time (Arvanitis and Miller, 1997, Miller et al., 1998). During 
long-term treatment, moderate weight gain and some glucose and lipid changes may occur 
(Brecher et al., 2007). 
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1.3.1.3. Risperidone 
Risperidone, a benzisoxazole derivative compound, is an effective atypical antipsychotic. 
This agent has potent antagonist properties for central dopamine D2 and 5-HT2 receptors; it 
also blocks adrenergic receptors (1, 2) and histamine receptors (H1) (Deeks, 2010, 
Muller-Siecheneder et al., 1998). It is described as having no affinity for cholinergic 
receptors. Its half-life may exceed 20 hours. Risperidone and its active metabolite, 9-
hydroxyrisperidone, are 90% and 77% plasma-protein-bound. Hydroxylation of the drug 
occurs primarily via CYP2D6 and CYP3A4 (Deeks, 2010, Goff, 2006). 
 Risperidone is increasingly being used for a number of different mental disorders, 
including schizophrenia (Carman et al., 1995, Claus et al., 1992, Deeks, 2010) and bipolar 
disorders (Bobo and Shelton, 2010, Woo et al., 2010). 
 Headache and dizziness are common side effects of risperidone treatment. In addition, 
unlike other atypical antipsychotics, risperidone can induce hyperprolactinemia. Although 
this agent produces slightly fewer extrapyramidal adverse effects than typical 
antipsychotics (Leucht et al., 1999), it has been associated with the development of 
metabolic disorders including obesity, dyslipidemia and diabetes (Lebovitz, 2003, Owenby 
et al., 2011). 
1.3.1.4. Ziprasidone 
Ziprasidone, a benzisothiazolylpiperazine, is an atypical antipsychotic agent with a unique 
chemical structure unrelated to any other SGA. It has a higher affinity for serotonin 
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(5HT2A) receptors than for dopamine (D2) receptors; it also has a low affinity for adrenergic 
(1) and histaminergic (H1) receptors. In addition, this molecule is a potent antagonist for 
5-HT2C and 5-HT1D and a potent agonist for 5-HT1A receptors. Ziprasidone may inhibit 
serotonin and norepinephrine re-uptake, which may explain its possible antidepressant 
effects (Keck et al., 2001, Komossa et al., 2009). 
 Ziprasidone is more than 99% bound to plasma protein and is metabolized by 
cytochrome P450 CYP3A4 and CYP1A2. Its half-life is seven hours (Daniel et al., 2006). 
It has been shown to improve schizophrenia symptoms, schizoaffective disorder, bipolar 
disorders and acute mania. It has a specific safety profile that predicts low liability for EPS 
and moderate weight gain. The most commonly reported adverse events of ziprasidone 
treatment are somnolence, insomnia and anxiety. Most of its side effects are dose-related. 
Weight gain and EPS have been reported as well; however, they are minor compared to 
other SGAs (Lincoln et al., 2010). The oral absorption of ziprasidone doubles when it is 
taken with food. 
1.3.1.5. Aripiprazole 
Aripiprazole, a quinolinone derivative, is an SGA with a mechanism of action that differs 
pharmacologically from those of other atypical antipsychotics. This agent is a potent partial 
agonist for dopamine D2 and serotonin 5-HT1A receptors, with antagonist activity for 
serotonin 5-HT2A. Aripiprazole is more than 99% bound to plasma protein and is 
metabolized by CYP2D6 and CYP3A4. Half-lives for aripiprazole and its major metabolite, 
dehydroaripiprazole, are 75 and 94 hours, respectively. Aripiprazole improves negative and 
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positive symptoms of schizophrenia. It has also been shown to be effective in acute 
treatment and relapse prevention for bipolar mania, resistant major depression and anxiety 
disorders. Aripiprazole has been associated with only minimal EPS and weight gain; in 
addition, no association with modification of lipid or glucose levels has been reported 
(McQuade et al., 2004, Printz and Lieberman, 2006b). 
1.3.2. Side effects of atypical antipsychotics 
1.3.2.1. Metabolic disturbances 
 The life expectancy of individuals suffering from severe mental disorders is shorter than 
that of the general population. About 75% of all deaths in mental disorders’ patients are 
related to physical illnesses; CVD is the most common cause of death (Brown et al., 2000). 
Patients with severe mental diseases are two to three times more at risk for obesity, 
metabolic syndrome and related morbidity and mortality than the general population 
(Correll et al., 2010, Holt et al., 2010). The prevalence of metabolic syndrome in patients 
with serious mental illness is approximately 50% (Holt et al., 2010). Factors that affect 
patients with severe mental illnesses and contribute to metabolic syndrome and diabetes 
mellitus include sedentary lifestyle, poor diet, smoking, adverse effects of SGAs and 
greater vulnerability to certain pathologies such as CVD and diabetes (Chacon et al., 2011).  
 SGAs are the first-line treatments for certain mental disorders, such as schizophrenia 
and affective disorders, in many countries. However, not all patients respond to SGAs and 
some of them remain intolerant of the drugs’ side effects. As we have seen, the therapeutic 
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objectives of the pharmacological treatment of mental disorders include the improvement 
of syndromes and quality of life, prevention of relapse and re-hospitalization and 
rehabilitation of patients (McIntyre et al., 2010). 
 Although SGAs are essential for the treatment of many psychiatric disorders, these 
medications are significantly associated with metabolic complications (such as obesity, 
glucose intolerance and dyslipidemia), diabetes mellitus, metabolic syndrome, CVD and 
premature death. These adverse events have evident impacts on patients’ quality of life and 
physical health; therefore, SGAs’ side effects on physical health have become an important 
issue in the treatment of mental illnesses. The literature reveals that SGAs’ liability to 
induce metabolic disturbances differs, often considerably, from one agent to another 
(Allison et al., 1999, Haddad, 2005, Newcomer, 2005).  
 In general, the highest risk of clinically significant weight gain has been reported for 
clozapine and olanzapine treatment. Treatment with quetiapine, risperidone and sertindole 
causes moderate weight gain. Amisulpride, ziprasidone and aripiprazole have the lowest 
risk of triggering weight gain. Based on the different receptor affinities of individual SGAs, 
it is suggested that these agents induce weight gain by different mechanisms. But, the exact 
nature of these mechanisms remains elusive. In addition, according to the literature, 
olanzapine and clozapine increase the risk of diabetes and dyslipidemia. The results for 
quetiapine and risperidone are controversial and need further inspection. Amisulpride, 
ziprasidone and aripiprazole do not seem to significantly change glucose levels or lipid 
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profiles (Haddad and Sharma, 2007, Leucht et al., 1999, Newcomer, 2005, Newcomer and 
Haupt, 2006).  
 In addition to its physical health risks, obesity can be embarrassing; it may be a source 
of distress and increased stress for patients with mental disorders. The reason why some 
patients show metabolic changes during antipsychotic treatment, while others do not, needs 
further investigation, but it is probably related to different genetics, diagnoses and lifestyle-
related factors in different patients. 
 Both schizophrenia and affective disorders are complex, polygenic, multi-factorial 
disorders. Even though bipolar disorder and schizophrenia differ in their neurobiology and 
phenomenology (McDonald et al., 2004, Muir et al., 2001, Murray et al., 2004), these 
disorders share some genetic features (Huang et al., 2010, Park et al., 2004, Peerbooms et 
al., 2010, Purcell et al., 2009). Although the pathophysiology of both disorders remains 
unclear, in recent years, investigations of the factors that contribute to SGA tolerability 
profiles in affective disorder and schizophrenia has emerged (De Hert et al., 2011b, Stahl et 
al., 2009, van Winkel et al., 2008).  
 It is noteworthy that, as with schizophrenia patients, in many studies the need of 
screening for metabolic syndrome in patients with bipolar disorder, or at least those who 
are being treated with SGAs, has been clearly demonstrated (de Almeida et al., 2011, van 
Winkel et al., 2008). Patients, families and clinicians need to know the differences among 
these SGA agents and also, whether there are differences related to particular psychiatric 
disorders. Determining the relative contributions of the antipsychotic treatment, patient 
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characteristics, unhealthy lifestyle and type of psychiatric illness is still an open, and very 
pertinent, question.   
1.3.2.2. Extrapyramidal side effects and movement disorders 
 Shortly after the first antipsychotics were prescribed in psychiatry, EPS were identified and 
reported (Steck, 1954). Acute EPS usually occur some days or even hours after the 
initiation of treatment. Common extrapyramidal syndromes include parkinsonism, 
akathisia, acute dystonia and tardive dyskinesia. EPS are important side effects because 
they can stigmatize patients, impair their quality of life, and lead to poor antipsychotic 
adherence and relapse (Haddad et al., 2011). Acute EPS have been reported in several 
studies as a major risk factor for later development of tardive dyskinesia in schizophrenia 
patients (Muscettola et al., 1999, Tenback et al., 2006). In general, when dopaminergic 
blockade in the striatum exceeds 75% to 80% of D2 receptors, antipsychotics cause EPS 
(Wilkaitis et al., 2006). Drugs with a higher affinity for D2 receptors lead to higher EPS 
incidence; for example, haloperidol treatment frequently causes EPS. Meta-analyses show 
that SGA treatment induces fewer EPS than haloperidol (Komossa et al., 2010, Leucht et 
al., 2009a, Rummel-Kluge et al., 2010a, Wilkaitis et al., 2006). Although SGAs have a 
more favourable profile of EPS than some FGAs (Komossa et al., 2010, Leucht et al., 
2009a, Rummel-Kluge et al., 2010a, Wilkaitis et al., 2006), studies and meta-analyses have 
shown that akathisia (Kane et al., 2009) and tardive dyskinesia (Kane, 2004)are also 
observed after SGA treatment. Differences between individual SGAs’ ability to induce EPS 
have been demonstrated in some studies (Gao et al., 2008, Rummel-Kluge et al., 2010a). 
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 With the increasing prescription of SGAs in psychiatry, it is worth examining the 
incidence of EPS in different phenotypes of mental disorders. Some studies have reported 
the same risk of EPS incidence further to SGA treatment in schizophrenia and bipolar 
disorder patients, while other studies have reported greater vulnerability to movement 
disorders in bipolar disorder patients (Cavazzoni et al., 2006, Gao et al., 2008, Nasrallah et 
al., 1988). However, the bipolar diagnosis as a risk factor for antipsychotic-induced EPS is 
still controversial. 
1.4. Meta-analysis method 
1.4.1. Definition of meta-analysis 
 Meta-analysis is a quantitative approach using statistical analysis to combine the outcomes 
of independent studies addressing a shared research hypothesis, in order to improve the 
reliability of the results. The validity of this method depends on the quality of the articles 
included in the meta-analysis. In order to answer a specific research question, individual 
studies usually report the collection of data from many participants; each participant is, 
therefore, a separate data-point in individual studies. In a meta-analysis, however, data from 
different studies that answer a single research question are collected and summarized; each 
study is, then, a separate data-point in the analysis. 
 Often, many of the individual trials fail to show a statistically significant difference 
between two treatments under study. However, significant benefits of a treatment may be 
shown when the results of individual studies are combined using a meta-analysis. It 
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increases the power of the analysis by using all of the information that is gathered in the 
systematic review. In addition, the accuracy of estimates of the effect size (treatment effect) 
increases in a meta-analysis (Borenstein et al., 2010, Borenstein.M, 2009, Sepehry, 2007). 
 Meta-analysis is a method that is useful for medicinal and social sciences in decision-
making, resolving conflicting evidence, answering questions where the answer is doubtful, 
explaining variability in practice, or simply confirming the suitability of current practice. 
Byers and Stullenbarger (2003) recognized meta-analysis as a bridge that connects clinical 
practice to research.  
1.4.2. Steps in meta-analysis 
In general, five separate steps should be performed in conducting a meta-analysis: problem 
formulation, literature search, coding, effect size calculation and data analysis and finally 
interpretation and presentation of results (Borenstein, 2009, Borenstein et al., 2010, 
Sepehry, 2007). 
1.4.2.1 Formulation of the problem and defining the hypothesis  
A well-defined statement that theoretically connects the variables under investigation is 
needed; therefore, we must carefully define the inclusion and exclusion criteria when 
locating potential studies. 
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1.4.2.2. Collecting all the available studies that provide data on the 
relationship 
A meta-analysis is only instructive if it adequately summarizes the existing literature, so a 
thorough literature search is critical to retrieve every relevant study. In order to gather 
maximum data, several search strategies are valuable: searches of the electronic databases 
(e.g., PubMed, PsycINFO and EMBASE), hand searching, conference proceedings, cross-
referencing and looking for unpublished studies by contacting pharmaceutical companies or 
searching on the clinicaltrials.gov website. The authors should be contacted to collect 
further information if one becomes aware of missing data. 
1.4.2.3. Inputting data (coding)  
Coding is a method of categorizing studies with a set of priori selected criteria. Coding is 
done to gather empirical findings from primary studies (e.g., treatment duration, sample 
size, study design, etc.) and input them into a statistical database. In this step, the 
collaboration of the authors of the primary studies is important to avoid any bias in the 
study selection. 
1.4.2.4. Effect size calculation and data analysis  
In this step, the overall effect size is calculated and the impact of moderating variables is 
analyzed. There are different statistical formulas to calculate effect size and analyze 
whether study characteristics influence effect sizes and cause heterogeneity. 
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1.4.2.5. Interpretation and reporting the results  
Analyzing the clinical implications, summarizing findings, discussing limitations and 
making recommendations are the tasks in this step (Borenstein, 2009, Borenstein et al., 
2010, Sepehry, 2007). 
1.4.3. Comprehensive meta-analysis  
Comprehensive Meta-Analysis (CMA) software was developed by a team of experts in 
meta-analysis. CMA version 2 was used for our meta-analytic approach in comparing 
SGAs’ side effects in schizophrenia and affective disorder patients. 
1.5. Research objective 
As mentioned above, five SGAs (olanzapine, quetiapine, risperidone, aripiprazole and 
ziprasidone) are considered in our meta-analysis. The steps below are followed in our 
study:  
1. Examine SGA-induced metabolic side effects in schizophrenia and bipolar disorder 
groups;  
2. Assess SGA-induced extrapyramidal adverse events;  
3. Compare the tolerability and safety profiles of atypical antipsychotics, as prescribed 
for bipolar disorders and schizophrenia; 
4. Assess whether moderating factors and studies’ characteristics play potential roles 
in explaining the heterogeneity and differences in the metabolic and extrapyramidal 
side effects experienced by schizophrenia and affective disorder patients.   
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Abstract 
Background: Olanzapine is prescribed for a number of psychiatric disorders including 
schizophrenia, bipolar mania, and unipolar and bipolar depression. Olanzapine treatment is 
associated with tolerability issues such as metabolic side effects (e.g. weight gain, increase 
in blood glucose, triglyceride and total cholesterol levels), extrapyramidal symptoms (e.g. 
parkinsonism, akathisia, tardive dyskinesia) and sedative side effects. Metabolic issues lead 
to some long-term consequences which include cardiovascular diseases and type-2 diabetes 
and these complications cause high rate of mortality and morbidity among patients with 
severe mental illnesses. The expanded indications of olanzapine in psychiatry suggest a 
need to investigate whether there is a difference in the incidence and severity of side effects 
related to category diagnosis. Are the side effects expressed differently according to 
phenotype?  Unfortunately, there are no reported studies that investigated these differences 
in side effects associated with olanzapine treatment in psychiatric patients with different 
phenotypes. 
Objective: The aim of the present meta-analysis is to separately examine olanzapine-
induced cardiometabolic side effects and extrapyramidal symptoms (EPS) in patients with 
schizophrenia (SCZ) and affective disorders (AD). 
Data sources: A search of computerized literature databases PsycINFO (1967-2010), 
PubMed, EMBASE (1980-2010) and clinicaltrials.gov website for randomized clinical 
trials was conducted. A manual search of reference lists of published review articles was 
carried out to gather further data. 
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Study selection: Randomized controlled trials were included in our study if (i) they 
assessed olanzapine side effects (metabolic or extrapyramidal) in adult patients with 
schizophrenia or affective disorders; and (ii) they administered oral olanzapine as 
monotherapy during study. 
Data extraction: Two reviewers independently screened abstracts for choosing articles and 
one reviewer extracted relevant data on the basis of predetermined exclusion and inclusion 
criteria. It should be mentioned that for the AD group we could only find articles related to 
the bipolar disorder (BP). 
Data synthesis: Thirty-three studies (4831 patients) that address olanzapine monotherapy 
treatment of adults with SCZ or BP were included in the analysis. The primary outcomes 
were metabolic side effects (changes in weight, blood glucose, LDL, total cholesterol and 
triglyceride levels). The secondary outcomes of our study were assessing the incidence of 
some extrapyramidal symptoms (parkinsonism, akathisia and use of antiparkinson 
medication). The tolerability outcomes were calculated separately for SCZ and BP groups 
and were combined in a meta-analysis. Tolerability outcomes show that olanzapine 
contributes to weight gain and elevates blood triglyceride, glucose and total cholesterol 
levels in both SCZ and BP patients. However, olanzapine treatment produced significantly 
more weight gain in SCZ patients than in BP patients. In addition, increases in blood 
glucose, total cholesterol and triglyceride levels were higher in the SCZ group compared to 
the BP group, even though these differences were not statistically significant. Based on our 
results; the incidence of parkinsonism was significantly higher in the SCZ group than in the 
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BP group. Subgroup analysis and logistic regression were used to assess the influence of 
treatment duration, dose, industry sponsorship, age and sex ratio on tolerability outcome.  
Conclusions: Our results suggest that SCZ patients may be more vulnerable to olanzapine-
induced weight gain. The findings may be explained by considering the fact that in addition 
to genetic disposition for metabolic syndrome in schizophrenia patients, they have an 
especially high incidence of lifestyle risk factors for cardiovascular diseases such as poor 
diet, lack of exercise, stress and smoking. It might be that an antipsychotic induces severity 
of side effect according to the phenotype. 
Keywords: Olanzapine, Schizophrenia, Affective disorders, Bipolar Disorders, Metabolic 
Syndrome, Extrapyramidal symptoms, Meta-analysis. 
2.1. Background 
Atypical antipsychotics (second-generation antipsychotics or SGAs) are widely prescribed 
for the treatment of multiple psychiatric conditions such as schizophrenia, bipolar disorder, 
major depressive disorder and anxiety disorder.
[1] 
Olanzapine is an atypical antipsychotic 
that is prescribed for acute mania,
[2, 3]
 bipolar depression,
[4]
 schizophrenia and bipolar 
mania.
[5, 6]
 It is an antagonist with a moderate to high affinity for the dopamine (D1–5), 
serotonin (5-HT2A, 2B, 2C, 3, 6), histamine (H1), α -adrenergic and muscarinic cholinergic (M1–
5) receptors.
[5]
  
 The main problem regarding the safety of antipsychotics, and particularly olanzapine, 
is weight gain and metabolic risks that lead to other complications such as diabetes mellitus 
and cardiovascular diseases (CVD).
[7]
 CVD are already recognized as the leading cause of 
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mortality and morbidity among patients with severe mental illnesses, such as schizophrenia, 
major depression and bipolar disorders.
[8, 9]
Risk factors for CVD such as obesity, 
hypertension, smoking, dyslipidemia, and diabetes are more frequent in schizophrenic and 
bipolar disorder patients than in the general population;
[10, 11]
 furthermore, SGAs may 
worsen CVD risk factors.
[11-13]
 Diabetes and CVD can significantly increase the rate of 
medical morbidity and mortality, affect quality of life and produce additional health care 
costs.
[14, 15]
 
 Extrapyramidal symptoms (EPS) including dystonia, parkinsonism and akathisia, are 
other common side effects of antipsychotic treatment.
[16]
 Although it is well known that 
atypical antipsychotics cause fewer EPS compared to typical antipsychotics,
[17, 18]
 studies 
have shown that EPS, including akathisia
[19]
 and tardive dyskinesia
[20]
 are also observed 
with some SGAs and a meta-analysis of head-to-head comparisons by Rummel-kluge et 
al.
[21] 
demonstrated differences between the SGAs in inducing EPS. Several studies have 
reported that acute EPS development is a major risk factor for later development of tardive 
dyskinesia in schizophrenia patients.
[22, 23] 
With the increasing use of SGAs in psychiatry, it 
is worth examining the incidence of EPS in different mental disorders. The presence of 
bipolar disease as a risk factor for antipsychotic-induced movement disorders is still 
unconvincing. Although some reports in the literature suggest that bipolar disorder patients 
are more likely to develop EPS than SCZ patients,
[24]
 the results of the pooled data analysis 
reported by Cavazzoni et al.
[16] 
showed that these findings may be representative of 
treatment with haloperidol, but not necessarily of olanzapine treatment.  
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 Although the pathophysiology of both disorders remains unclear, in recent years, the 
investigation of the factors which contribute to the different SGAs tolerability profiles 
between SCZ and BP has just begun.
[25, 26] 
Given that SGAs are prescribed for different 
diagnoses, it would be interesting to see whether the side effects have a different expression 
according to phenotype.  
 Some authors indicate possible inherent genetic vulnerability to metabolic irregularity 
in schizophrenia patients,
[27-29]
 although some other studies are not in line with this 
suggestion.
[30, 31]
 Results from a comprehensive, naturalistic screening program
[26]
 showed 
that the prevalence of the metabolic syndrome in schizoaffective patients was higher 
compared to schizophrenia and bipolar disorders patients. They suggest a possible 
increased inherent genetic vulnerability to metabolic syndrome in schizoaffective patients. 
Unadjusted odds ratio for metabolic syndrome did not statistically differ between bipolar 
disorder and schizophrenia patients in their study; however, the differences were 
statistically significant after adjustment.  
 If there is a difference, it could mean that a phenotype per se influences a medication’s 
safety and tolerability. What might be the biological mechanism involved in these 
differences? What could we learn about a disease if there is such a difference? 
Schizophrenia is a polygenic and multi-factorial complex disorder in which a myriad of 
different genes are potentially involved. The phenotypic expression of the disease in 
conjunction with epigenetic and environmental phenomena needs to be better understood. 
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Bipolar disorders are also heterogeneous and share some genetic features with 
schizophrenia.
[26, 32-34]
 
 
 The objective of this research was to compare the tolerability and safety profiles of 
olanzapine as prescribed for bipolar disorders and schizophrenia. To the best of our 
knowledge, no meta-analysis has previously compared the metabolic and extrapyramidal 
side effects of olanzapine for different mental diseases. We therefore conducted a meta-
analysis of studies in order to compare olanzapine side effects in patients with 
schizophrenia and bipolar disorders. We hypothesized that phenotype of disease may affect 
induction and severity of olanzapine side effects. With the increasing use of SGAs in 
psychiatry, this investigation is valuable not only to inform clinicians but also to provide 
clues to the pathophysiology of schizophrenia and bipolar disorders. 
 
2.2. Methods 
2.2.1. Data sources and search strategy 
A systematic review of the literature on olanzapine for the treatment of schizophrenia 
(SCZ) and affective disorders (AD) that reported randomized controlled trials (RCTs) was 
performed. The keywords used for the search were olanzapine, atypical antipsychotics and 
schizophrenia or bipolar disorder, bipolar depression, manic disorder, bipolar affective 
disorder, bipolar mania, major depression and unipolar disorder. The search engines were 
PsycINFO (1967–2010), PubMed (MEDLINE), EMBASE (1980–2010) and 
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clinicaltrials.gov website. There were no limitations on language. A hand search of 
published review articles, as well as cross-referencing, was carried out to gather further 
data. Authors of the studies that met inclusion criteria were contacted to provide the 
unreported data. Two reporters independently checked all reports for inclusion and 
exclusion criteria. 
2.2.1.1. Inclusion criteria 
Studied were searched and divided into two groups: schizophrenia and bipolar disorder. 
Inclusion criteria were studies that contained (1) adult patients (18–65 years old) which had 
a diagnosis of schizophrenia or affective disorders; (2) randomized controlled trials, open-
label or double-blind; (3) oral monotherapy treatment of olanzapine; (4) fixed- and flexible-
dose studies with a duration of three weeks or longer; and (5) reported data on metabolic or 
extrapyramidal side effects with olanzapine treatment. 
2.2.1.2. Exclusion criteria 
Trials in both groups were left out if they contained (1) combination therapy of olanzapine 
with another agent such as an anti-manic, antidepressant or other antipsychotic medication; 
(2) psychotic diagnosis other than schizophrenia such as schizoaffective or 
schizophreniform disorders; (3) incomplete or unavailable data; (4) study groups of 
children or adolescents; (5) non-randomized methods; or (6) treatment with olanzapine 
depot injection (because no related study was found in the BP group). 
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2.2.2. Data extractions and outcome parameters 
Two reviewers (H.M and E.S) independently checked abstracts for each diagnostic group 
and chose related articles, then one reviewer (H.M) extracted data to ensure that they met 
the inclusion criteria. Trial abstracts were screened initially, and then in the second step full 
texts were reviewed. Data and articles from the schizophrenia and bipolar disorders group 
were analyzed separately to compare the results of the two groups. The data extractions 
were separated along two dimensions: (a) clinically important metabolic side effects 
including change in weight, glucose, LDL, HDL, triglyceride and total cholesterol levels 
were separately assessed in each group. Weight change was reported as the change in 
kilograms from baseline to endpoint; the changes in other metabolic parameters were 
defined as the change in mg/dl from baseline to endpoint. (b) some EPS-related adverse 
events were chosen as second outcome. Outcome variables were the incidence of some 
EPS-related side effects (e.g. parkinsonism, antiparkinson medication use and akathisia), as 
measured by treatment-emergent adverse event data. 
2.2.3. Meta-analytic calculations 
Continuous outcomes were analyzed by estimating means and confidence intervals for each 
group of subjects: SCZ and AD. Using Comprehensive Meta-Analysis (CMA),
[35] 
effect 
size estimates for continuous outcomes were calculated from the mean, standard deviation 
and sample size for each group of subjects. The moderator was diagnostic type (DT), which 
varied between studies. Dichotomous outcomes (incidence of akathisia, parkinsonism and 
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use of antiparkinson medication) were estimated based on events and sample size for each 
group of patients (SCZ and AD) and reported as event rates. Then, we compared the point 
estimates of each group to see whether the difference between the points was significant or 
not. The level of significance for the effect size estimates was set at p=0.05. For all 
analyses, effect size estimates were pooled with the random-effects model, which is more 
strict than fixed-effects model and permits population-level inferences as well.
[36] 
We 
examined the heterogeneity of study with the I-squared statistic, supposing that I
2
 statistics 
greater than 50% proposed considerable heterogeneity. Level of significance was set at 
p<0.1. 
2.2.3.1. Sub-analyses and addressing potential confounding factors 
Sub-analyses, including between-group differences, were carried out for potential 
confounding factors in age, sex ratio and daily dose. The effects of treatment duration on 
the results were examined by performing subgroup analyses including short-term (12≤ 
weeks) and longer term studies, separately. To analyze pharmaceutical company 
sponsorship effects, a subgroup analysis was done as well. Logistic regression analyses 
were used to determine association of sex ratio with the tolerability outcome. 
2.3. Results 
2.3.1. Study characteristics 
The search strategy identified 688 articles which were related to the schizophrenia group 
and 255 articles were found for the affective disorders group. Among these, 910 were 
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discarded according to the following criteria: (1) duplicating: 317 studies, (2) type of 
article/study (e.g., case study, review, letter to the editor and crossover study): 313 studies; 
(3) type of population (e.g., non randomized, nonschizophrenia patients, age range): 108 
studies; (4) treatment type (e.g., combination therapy or depot olanzapine injection): 73 
studies; (5) incomplete or unavailable data: 99 studies. As a result, 33 studies
[3, 37-68]
 
(n=4831) were accepted for both groups: for SCZ patients N=19, n=2389
1
 and for AD 
group N=14, n=2442. It should be mentioned that for the AD group we could only find 
articles related to the bipolar disorder (BP); we could not find related studies on other 
affective disorders, considering our inclusion criteria. More information on the sorting 
process in each group is shown in figure 1. In addition, Table 1 provides details of 
demographic characteristics among studies included in the meta-analysis. 
2.3.2. Outcome results 
2.3.2.1. First outcome measure: metabolic changes 
(a) Weight gain 
Thirty-one studies (n=4488), 18 for the SCZ (n=2196) and 13 for the BP group (n=2292), 
were accepted and checked for changes in weight (kg) in the sample. Analysis revealed an 
increase in weight in both groups; however, the SCZ group showed significantly more 
weight gain than the BP group (3.13 kg vs. 2.27 kg, respectively; p=0.020). Details are 
shown in Figure 2. 
                                                 
1 “N” refers to the number of articles whereas “n” is the number of patients. 
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(b) Cholesterol change 
Thirteen studies (n= 2723), six for the SCZ (n=1011) and seven for the BP group (n=1712), 
were examined for changes in blood cholesterol levels (mg/dl). Even though the increase 
from baseline is clear in both groups, there was no statistically significant difference 
between the two groups (11.7 mg/dl in SCZ group vs. 9.9 mg/dl for BP group; p=0.771) 
(Figure 3). 
(c) Glucose change 
Fifteen studies (n=2825), seven for the SCZ (n=1105) and eight for the BP group (n=1720), 
were compared for changes in blood glucose levels (mg/dl). In spite of the fact that 
olanzapine changed the levels of glucose in both groups, the difference was not statistically 
significant between SCZ and BP groups (5.6 vs. 2.02 mg/dl, respectively; p=0.116) (Figure 
4). 
(d) Triglycerides change 
Six studies (n=1165), two for the SCZ (n=551) and four for the BP group (n=614), were 
evaluated for changes in blood triglyceride levels (mg/dl). There was no statistically 
significant difference between the two groups (38.2 vs. 26.1 mg/dl, respectively; p=0.064), 
although the levels of triglycerides changed after taking olanzapine for both groups (Figure 
5). 
(e) LDL and HDL change 
We could not find enough studies to compare LDL and HDL changes between the two 
groups. 
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2.3.2.2. Second outcome measure: extrapyramidal side effects 
EPS-related adverse event rates and their intensity were low in both groups; however, there 
were some significant differences in the frequency of parkinsonism between the two 
groups. 
(a) Incidence of akathisia 
The akathisia event rate did not differ significantly between the groups. Based on eight 
articles included in the BP group (n=1575), the event rate was 6.3%; according to eleven 
articles in the SCZ group (n=1475), the incidence of akathisia was 7.8% (p=0.468) (Figure 
6). 
(b) Incidence of parkinsonism 
The incidence of parkinsonism was significantly higher in the SCZ group. Based on seven 
articles included in the BP group (n=1460), the event rate was 3.1%; in six articles in the 
SCZ group (n=884), the incidence of parkinsonism was 13.9% (p=0.005) (Figure 7). 
(c) Antiparkinson medication use  
Antiparkinson medication use did not differ significantly between two groups. According 
to four articles included in the BP group (n=926), the event rate was 6.7%; in eight articles 
in the SCZ group (n=1099), the use of such medication was 13.7% (p=0.184) (Figure 8). 
2.3.2.3. Heterogeneity 
Heterogeneity of all outcomes (metabolic and extrapyramidal) were explored by I
2
 statistic; 
they were all heterogeneous (I
2
>50%). Sub-analyses were assessed to determine possible 
sources of heterogeneity in results. 
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2.3.3. Sub-analyses  
2.3.3.1. Age 
All studies reported mean age and standard deviation (SD) of participants. No significant 
difference was observed between the two groups: 38.9(11) and 39.7(11.9) years for studies 
in SCZ and BP groups, respectively. See Table 1 for more information on demographic 
characteristics among studies included in the meta-analysis. 
2.3.3.2. Sex ratio 
Sex ratio was also reported in all studies. Significantly more males participated in SCZ 
group studies compared to BP groups; male percentage in SCZ group: N=2389; 1612 
(67%) was compared to male ratio in BP group: N=2442; 1135 (46%); p=0.000.  
 Considering the significant difference in sex ratio between SCZ and BP patients’ 
groups, this variable was included in the statistical analysis as a regressor. For this meta-
regression on weight gain and parkinsonism incidence, we found that in the SCZ patients’ 
group, weight gain and parkinsonism incidence were inversely related to male ratio. As 
weight gain and parkinsonism incidence were significantly higher in SCZ, and male 
percentage was also higher in this group, outcome differences between the two groups seem 
not related to sex ratio.   
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2.3.3.3. Dose  
Based on eight studies in BP and eight in SCZ groups which specified mean daily dose, no 
difference was observed between the two groups: SCZ group 14.6(4.9) mg/day and BP 
group 13.5(5) mg/day. 
2.3.3.4. Company sponsorship 
The studies were stratified based on industry sponsorship. By considering only the studies 
with industry sponsorship, 14 studies were found in the BP group and 13 in SCZ group. By 
running meta-analyses between the stratified BP and SCZ groups, outcomes remained the 
same as the main analysis for levels of blood total cholesterol levels and weight gain, and 
the incidence of akathisia and antiparkinson medication use. In addition, we observed 
significantly higher glucose levels in the SCZ group compared with the BP group (7.5 
mg/dl vs. 2.6 mg/dl, respectively; p=0.01). It should be mentioned that we could not find 
non-sponsored studies for the BP group. 
2.3.3.5. Treatment duration 
We stratified the studies based on treatment duration. Short-term studies (between 3 and 12 
weeks) displayed that the results of primary and secondary outcomes remained the same as 
the main analysis for levels of total cholesterol and glucose, and the incidence of akathisia, 
antiparkinson medication use and parkinsonism. The results for weight gain were, however, 
different. Nineteen studies, eleven for the BP (n=2231) and eight for the SCZ group 
(n=262), in which weight changes have been reported for short-term treatment, were 
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compared together. Even though weight gain was higher in the SCZ group, this difference 
was no longer statistically significant (2.18 vs. 2.94 kg, respectively; p=0.226). For studies 
more than 12 weeks, we did not have enough data in the BP group. 
2.4. Discussion 
Metabolic syndrome is a significant public health problem in patients with mental illnesses 
and particularly schizophrenia. Recently, atypical antipsychotic agents have been linked to 
several forms of morbidity, including obesity, hyperlipidemia and type-2 diabetes mellitus, 
which predict metabolic syndrome, cardiovascular morbidity and malignancy.
[67, 69, 70]
 The 
mechanisms responsible for an association between schizophrenia, antipsychotic treatment 
and metabolic syndrome still remain unclear.
[71] 
 The aim of our meta-analysis was to investigate the difference between olanzapine side 
effects in schizophrenia and bipolar disorder patients. To our knowledge, this is the first 
meta-analysis comparing SCZ and BP patients with regard to metabolic and extrapyramidal 
side effects of olanzapine in randomized controlled trials. Based on the different 
phenotypes of these mental illnesses and the frequent use of SGAs to treat them, studying 
the degree of sensitivity and tolerability to SGAs in BP and SCZ patients seems essential. 
Our results revealed that all metabolic parameters increased from baseline for both groups. 
Furthermore, these changes were statistically significant for mean weight gain in the SCZ 
group compared to the BP group.  
 As many studies indicate, SGA medications associate with weight gain, and our 
findings are consistent in this regard. In a meta-analysis
 
comparing all SGAs head to head, 
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significantly higher weight gain was seen with clozapine and olanzapine treatment 
compared to other antipsychotics.
[11]
 These results are generally similar to the findings of a 
systematic review reporting metabolic adverse effects among different SGAs in children 
and adolescents, showing that olanzapine was the most likely to lead to weight gain.
[72]
 
Another randomized comparative study
[73]
 also reported that olanzapine produced more 
weight gain and glucose level increase compared to amisulpride during a 6-month trial. The 
mechanism of olanzapine-induced weight gain remains obscure at present; however, 
several factors could account for it, such as a high affinity of this medication to histamine-
H1, serotonin 5-HT2c and M1 muscarinic cholinergic receptors.
[56, 74-77] Olanzapine’s high 
affinity to these receptors is associated with appetite changes, increased food intake and 
sedation. Genetic data also propose a role of leptin receptor activity, G-protein signaling, 
cannabinoid receptor activity and promelanin-concentrating hormone signaling in the 
SGAs’ weight gain.[78, 79] 
 We also examined the mean changes in lipid profile and glucose level in both patients’ 
groups. Our meta-analysis showed increases in the mean levels of blood glucose, total 
cholesterol and triglycerides in both groups. The metabolic changes are higher in the SCZ 
group compared to the BP group; however, the differences between these groups were not 
statistically significant.  
 Even though the mechanism for olanzapine’s effect on glucose level and insulin 
resistance is poorly understood, there is some indication that the long-term use of 
olanzapine may decrease insulin secretion, which may lead to hyperglycemia.
[80] 
A 
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proposed mechanism for hyperglycemia is related to the drug’s affinity for the H1, M3 and 
5-HT2C receptors, which is correlated with an increased risk of diabetes.
[81] 
Another possible 
mechanism for the increase of insulin resistance with olanzapine treatment could be by 
impairing the ability of insulin to stimulate glucose uptake into peripheral tissues such as 
skeletal muscle and adipose tissue. There is recent evidence indicating that polymorphism 
in 5-HT2A and 5-HT2C receptor coding genes, HTR2A and HTR2C, seems to be associated 
with development of metabolic abnormalities such as C-peptide and insulin elevation 
during olanzapine and clozapine treatment.
[82-84]
  
 Some SGAs are associated with dyslipidemia, including increased levels of LDL, total 
cholesterol and triglycerides, which can result in CVD.
[85] 
At present, the exact mechanism 
underlying changes in lipids due to certain SGA treatments is unknown. Several hypotheses 
have been proposed regarding biological factors such as weight gain, dietary changes and 
the development of glucose intolerance to explain the high frequency of dyslipidemia with 
specific antipsychotic medications. 
[86, 87] 
 Albaugh et al.
[88] 
recently proposed an interesting mechanism to explain why 
olanzapine contributes to metabolic side effects leading to obesity and diabetes. In their 
animal model, they indicated that chronic administration of olanzapine has at least five 
effects on predisposing male rats to increased adiposity. These effects are decreased 
physical activity, impaired glucose and insulin tolerance, increased tendency to
14
C-2-
deoxyglucose and free fatty acid (FFA) uptake into fat depots, increased adipose tissue 
lipogenesis and impaired lipolysis. Recently, results of a 3-months prospective open label 
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study showed a significant decline in adiponectin levels, an adipocytes-derived hormone 
that increases insulin sensitivity, for olanzapine-treated patients compared to risperidone-
treated patients.
[89] 
The observed reduction in plasma adiponectin levels in olanzapine-
treated patients may suggest a direct effect of olanzapine on the adipose tissue and explain 
partially the increased metabolic risk in these patients. 
 As our second outcome, we examined extrapyramidal symptoms related to olanzapine 
treatment between schizophrenia patients and those with bipolar disorder. Most published 
placebo-controlled studies show that the rate of akathisia is similar for olanzapine and 
placebo in both schizophrenia and bipolar disorder,
[19] 
which is consistent with our results. 
The difference found between the two groups of patients for the incidence of akathisia was 
not significant. Our results revealed that even with the low incidence of parkinsonism in 
patients treated with olanzapine, parkinsonism was observed significantly more often in the 
SCZ group compared to the BP group. The use of antiparkinson medication was also 
checked and it was higher in the SCZ group; however, this difference was not significant.  
 Cavazzoni and his research group compared olanzapine-induced extrapyramidal 
symptoms in bipolar mania and SCZ patients in a pooled analysis.
[16]
 They indicated the 
same results as us, namely that parkinsonism incidence in SCZ patients was higher than in 
bipolar patients; however, the use of antiparkinson medication was similar for both groups.  
 The reduced incidence of EPS during treatment with atypical antipsychotic agents is 
thought to happen because of their unique receptor-binding profiles.
[90]
 In a review by Gao 
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et al.
[91]
 it is mentioned that olanzapine did not produce more akathisia, parkinsonism or use 
of antiparkinson medication in bipolar groups compared to SCZ groups.  
 As expected, effect size estimates were heterogeneous across studies. A secondary 
objective was, therefore, established to identify the factors contributing to this 
heterogeneity. Because of concerns that socio-demographic characteristics among different 
studies included in our meta-analysis might have influences on our results and cause 
heterogeneity, we conducted logistic regression assessing the effect of various baseline 
characteristics (sex ratio, age, daily dose and industry sponsorship) on weight gain and 
parkinsonism incidence. In the BP patients’ group, none of these baseline variables had any 
noticeable effect on parkinsonism incidence. In the SCZ group, however, parkinsonism 
incidence and weight gain showed a reversed dependency on the male ratio, by using a 
meta-regression. As weight gain and parkinsonism incidence were significantly higher in 
SCZ, and male percentage was also higher in this group, outcome differences between the 
two groups still remain significant.  
 As mentioned earlier, we also stratified the studies based on treatment duration. Short-
term studies displayed that parkinsonism incidence was significantly higher in the SCZ 
group. Weight gain level was also higher in the SCZ patients; however, this difference was 
no longer statistically significant. For studies more than 12 weeks, data unavailability in the 
BP group prevented us from performing the same analysis. Conducting studies on long-
term safety of antipsychotics drugs should be considered a priority in psychopharmacology, 
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as treatment with antipsychotics is often continued for a long period of time or even for the 
patients’ whole life.  
     Taken together, these results do not suggest that population differences in sex ratio, age 
and daily dose significantly influenced our results. Furthermore, as no non-sponsored study 
was available for the BP group, we could not assess the industry-sponsorship effects in it; 
however, by comparing the industry-sponsored studies between the two groups of patients, 
weight gain, glucose level and parkinsonism incidence were significantly higher in the SCZ 
group. Treatment duration was also considered and discussed above. The remaining 
heterogeneity of effect size estimates across studies, even after performing numerous sub-
analyses, raises the possibility that factors such as life style and disease phenotype in our 
comparison groups may contribute to these results. 
 Some limitations affect this meta-analysis which may confound our results and 
determine the necessity to interpret the current results with caution. In particular, relatively 
few studies were available for direct comparison of SGAs side effects among BP vs. SCZ 
patients; therefore, we obtained data from articles focusing on either SCZ or BP patients 
and then compared the results of both groups. In addition, in our comparison there was no 
placebo control group, which may restrict the interpretation of our results. To cope with this 
limitation, prospective controlled trials are required specifically to determine a possible 
relationship between psychiatric diagnosis and olanzapine-induced side effects. Second, 
due to the retrospective nature of this analysis, information on severity of psychiatric illness 
could not be considered in this analysis. Another limitation of this meta-analysis is 
  
 
52
unavailability of data for depot administration of olanzapine in the BP group; in our study 
only oral monotherapy with olanzapine is included. Finally, we did not examine the impact 
of previous exposure to antipsychotic treatment, race/ethnicity and initial weight in both 
groups, which may impact the generalizability of our findings. These variables should be 
more deeply considered in future studies. 
 In conclusion, side effects are important to consider for prescribers because the efficacy 
of treatment may be reduced due to the presence of certain side effects. The results of our 
meta-analysis suggest that schizophrenia patients may be more vulnerable to olanzapine-
induced weight gain. This meta-analysis proposes that factors such as life style and disease 
phenotype may contribute to this susceptibility in SCZ group. Patients with severe mental 
illnesses need to be informed of the different side effects induced by olanzapine treatment 
and they should be monitored regularly, especially for metabolic issues. In several domains, 
we can only conclude, based on our findings, that metabolic side effects are lower in the BP 
group compared to the SCZ group. However, it is unclear what that means for a patient and 
how it would change our follow-up.  
 It is also important to consider that BP patients are more prone to receive 
polypharmacy (a combination of mood stabilizers, antidepressants and antipsychotics) 
compared to SCZ patients. Therefore, clinicians should take into account the risk of 
metabolic side effects associated with antipsychotic drugs (which is confirmed in our meta-
analysis) when prescribing atypical antipsychotics for BP patients. In a recent review, 
Taylor et al.
[92]
 emphasized the necessity of respecting guidelines for screening and 
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monitoring metabolic side effects in patients with severe mental illnesses, since physical 
health problems are one of the most common causes of premature death in people with 
chronic mental illnesses.  
 Compared with the general population, people with schizophrenia and bipolar disorder 
have an increased risk of obesity.
[79]
 Our results, consistent with other studies,
[13, 93]
 indicate 
that weight gain and increase in blood glucose, total cholesterol and triglyceride levels are 
also present in BP patients’ group with olanzapine treatment. Our study supports the 
recommendation of regular screening and accurate monitoring of these patients. 
Furthermore, appropriate psychoeducation on lifestyle modification programs including 
weight control, healthy diet and increased physical activity are important to prevent and 
treat the metabolic syndrome and CVD in patients with severe mental disorders. 
 As mentioned previously in a review article, structural and functional variations in the 
genome cause proteomic and metabolomic imperfections associated with the disease 
phenotype. 
[94]
 Genetic polymorphism may be an important factor that contributes to the 
difference in metabolic side effects of SGAs between SCZ and AD patients. In addition to a 
genetic predisposition for metabolic syndromes among schizophrenic patients, lifestyle risk 
factors such as stress, poor diet, lack of exercise and smoking are common in schizophrenic 
patients.
[82, 95]
  
 In order to achieve a mature discipline of pharmacogenomics of schizophrenia and 
bipolar disorder it would be relevant to promote the education of prescribers and the public 
for the use of genomic screening in clinical practice; pharmacogenomic protocols need to 
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be validated according to drug category and phenotype in order to optimize efficiency. 
Obviously, these findings need further investigation and the variable confounders are still 
to be clarified. 
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Table legends 
Table 1 Demographic characteristics among bipolar and schizophrenia studies included 
in the meta-analysis 
 
Tables  
Table 1 
Diagnostic type/Study Age (mean± SD),y Dose(mean± 
SD),mg/day 
Treatment  
duration, w 
Male/Female, 
N 
Bipolar Disorder     
McIntyre et al. Dec. 2009 39.6±11.9 5-20 12 135/94 
Tohen et al. 2006 41.4±12.1 11.8±7.5 12 87/138 
Tohen et al. 2008 39.5±11.9 11.4±2.49 3 99/116 
Tohen et al. Nov. 2003  42.2±12.5 9.7 8 141/229 
Tohen et al. 1999 39.5±11 14.9±5 3 35/35 
Tohen et al. 2000 38.3±10.7 16.4±4.2 4 27/28 
Sanger et al. 2003 39.1±10.9 5-20 3 10/9 
Tohen et al. 2009 39.5±10.9 5-20 48 29/47 
McIntyre et al. Nov. 2009 40.1±11.3 15.8±2.3 3 114/76 
McIntyre et al. April 2010 38.4±10.4 15.9±2.5 3 117/88 
McIntyre et al. Nov. 2010 38.7±12.4 15.7±4.1 40 68/39 
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Tohen et al. Dec 2003 41±13 11.4±5.3 12 86/148 
NCT00510146* 35.93±11.13 5-20 6 138/205 
NCT00129220* 
 
43.12±12 5-20 6 49/55 
Schizophrenia     
McQuade et al. 2004 38.2±11 16.5 26 115/46 
Kane et al. 2009 38.3±10.5 16.7 28 194/87 
Wu et al. 2006 34.2±10.3 10–20 6 25/11 
Bhowmick et al. 2010 31.4±7.7 10-20 12 20/18 
Saddichha et al. 2007 26.7±6.4 17±5 8 94/46 
Beasley et al. 1996  38±9.3 10 8 16/19 
Riedel et al. 2007 34.47±11.6 15.82±5.44 8 11/6 
Chan et al. 2010 40.8±11.5 11.72±4.87 8 14/10 
Lieberman et al. 2005 40.8±10.8 20.1 72 244/92 
Sirota et al. 2006 36.2±10.9 16±3.3 11 17/4 
Dollfus et al. 2005 39±9 5–15 6 11/18 
Bitter et al. 2004 37.6±9.3 17.2±4.8 18 46/30 
Breier et al. 2005 40.1±11.6 15.27±4.52 28 180/97 
Alvarez et al. 2006 37±10.6 12.2±5.8 52 85/39 
Lecrubier et al. 2006 37.25±10.75 5, 20 24 37/13 
Vanelle et al. 2006 36.5±8 11.4±2.8 8 23/17 
NCT00320489* 40.12±10.84 5-20 104 177/83 
NCT00645099* 37.5±11.4 10-15 24 133/87 
NCT00145496* 42.8±11.27 5-20 24 170/54 
*Unpublished studies 
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Figure legends 
Figure 1 Flow Diagram Describing the Search Process (Quality of Reporting of 
Meta-analysis (QUOROM) 
Figure 2 Forest plot of the effect size estimates of weight changes (kg) in 
schizophrenia compared to bipolar disorder patients (p=0.020). CI: 
confidence interval, DT: diagnostic type, SCZ: schizophrenia patients, BP: 
bipolar disorder. 
Figure 3 Forest plot of the effect size estimates of cholesterol changes (mg/dl) in 
schizophrenia compared to bipolar disorder patients (p=0.771). CI: 
confidence interval, DT: diagnostic type, SCZ: schizophrenia patients, BP: 
bipolar disorder patients. 
Figure 4 Forest plot of the effect size estimates of glucose changes (mg/dl) in 
schizophrenia compared to bipolar disorder patients (p=0.116). CI: 
confidence interval, DT: diagnostic type, SCZ: schizophrenia patients, BP: 
bipolar disorder patients. 
Figure 5 Forest plot of the effect size estimates of triglycerides changes (mg/dl) in 
schizophrenia compared to bipolar disorder patients (p=0.064). CI: 
confidence interval, DT: diagnostic type, SCZ: schizophrenia patients, BP: 
bipolar disorder patients. 
Figure 6 Forest plot of the effect size estimates of akathisia incidence in 
schizophrenia compared to bipolar disorder patients (p=0.468). CI: 
confidence interval, DT: diagnostic type, SCZ: schizophrenia patients, BP: 
bipolar disorder patients. 
Figure 7 Forest plot of the effect size estimates of parkinsonism incidence in 
schizophrenia compared to bipolar disorder patients (p=0.005). CI: 
confidence interval, DT: diagnostic type, SCZ: schizophrenia patients, BP: 
bipolar disorder patients. 
Figure 8 Forest plot of the effect size estimates of antiparkinson medication use in 
schizophrenia compared to bipolar disorder patients (p=0.184). CI: 
confidence interval, DT: diagnostic type, SCZ: schizophrenia patients, BP: 
bipolar disorder patients. 
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Figures 
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Figure 1  
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BP McIntyre et al.April 2010 2.600 0.251 2.107 3.093
BP McIntyre et al. Dec. 2009 3.800 0.324 3.165 4.435
BP McIntyre et al. Nov. 2009 1.900 0.233 1.444 2.356
BP McIntyre et al. Nov. 2010 6.000 0.638 4.749 7.251
BP NCT00510146 2.450 0.153 2.150 2.750
BP Sanger et al. 2003 1.780 0.424 0.948 2.612
BP Tohen et al. 1999 1.650 0.304 1.055 2.245
BP Tohen et al. 2000 2.110 0.385 1.355 2.865
BP Tohen et al. 2006 1.000 0.347 0.321 1.679
BP Tohen et al. 2008 1.300 0.169 0.969 1.631
BP Tohen et al. 2009 0.120 0.586 -1.029 1.269
BP Tohen et al. Dec 2003 2.820 0.293 2.246 3.394
BP Tohen et al. Nov. 2003 2.590 0.174 2.249 2.931
BP 2.278 0.248 1.791 2.764
SCZ Alvarez et al. 2006 3.800 0.557 2.709 4.891
SCZ Beasley et al. 1996 2.200 0.566 1.091 3.309
SCZ Bhowmick et al. 2010 4.700 0.191 4.325 5.075
SCZ Bitter et al. 2004 3.300 0.608 2.108 4.492
SCZ Breier et al. 2005 3.060 0.419 2.239 3.881
SCZ Chan et al. 2010 1.610 0.524 0.583 2.637
SCZ Dollfus et al. 2005 2.100 0.566 0.991 3.209
SCZ Kane et al. 2009 3.400 0.659 2.108 4.692
SCZ Lecrubier et al. 2006 2.430 0.482 1.486 3.374
SCZ Lieberman et al. 2005 4.300 0.409 3.499 5.101
SCZ McQuade et al. 2004 4.230 1.187 1.903 6.557
SCZ NCT00145496 2.600 0.027 2.547 2.653
SCZ NCT00320489 2.180 0.455 1.289 3.071
SCZ NCT00645099 3.810 0.401 3.024 4.596
SCZ Riedel et al. 2007 3.760 0.672 2.443 5.077
SCZ Saddichha et al. 2007 5.000 0.594 3.835 6.165
SCZ Sirota et al. 2006 2.300 0.814 0.705 3.895
SCZ Vanelle et al. 2006 1.450 0.866 -0.248 3.148
SCZ 3.138 0.274 2.601 3.675
Overall 2.665 0.184 2.305 3.026
-4.00 0.00 4.00 8.00
Decreased
weight level
Increased
weight level
Group by
DT
Study name Statistics for each study Mean and 95% CI
Standard Lower Upper
Mean error limit limit
 
Figure 2 
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BP McIntyre et al.April 2010 13.900 2.403 9.191 18.609
BP McIntyre et al. Dec 2009 12.400 2.273 7.945 16.855
BP McIntyre et al. Nov  2009 11.400 2.364 6.767 16.033
BP NCT00510146 9.360 1.634 6.157 12.563
BP Tohen et al. 2008 3.900 1.950 0.078 7.722
BP Tohen et al. Dec 2003 14.000 2.141 9.804 18.196
BP Tohen et al. Nov 2003 6.000 1.664 2.738 9.262
BP 9.944 1.487 7.028 12.859
SCZ Breier et al. 2005 3.120 2.527 -1.832 8.072
SCZ Kane et al. 2009 4.100 2.955 -1.692 9.892
SCZ Lieberman 2005 9.700 2.100 5.583 13.817
SCZ McQuade et al. 2004 16.300 3.473 9.494 23.106
SCZ Vanelle et al. 2006 6.187 7.458 -8.431 20.805
SCZ Wu et al. 2006 29.250 1.115 27.066 31.434
SCZ 11.695 5.822 0.284 23.107
Overall 10.051 1.441 7.226 12.876
-15.00 0.00 15.00 30.00
Group by
DT
Study name Statistics for each study Mean and 95% CI
Standard Lower Upper
Mean error limit limit
Decreased
cholesterol level
Increased
cholesterol level
 
Figure 3 
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BP McIntyre et al. April 2010 2.300 1.048 0.247 4.353
BP McIntyre et al. Dec 2009 3.100 1.216 0.717 5.483
BP McIntyre et al. Nov  2009 -0.400 2.080 -4.477 3.677
BP NCT00510146 1.800 0.614 0.597 3.003
BP Sanger et al 2003 -1.440 7.970 -17.061 14.181
BP Tohen et al. 2008 1.800 1.286 -0.720 4.320
BP Tohen et al. Dec 2003 -0.190 2.376 -4.847 4.467
BP Tohen et al. Nov 2003 4.000 1.610 0.844 7.156
BP 2.025 0.420 1.201 2.849
SCZ Breier et al. 2005 5.040 2.003 1.115 8.965
SCZ Kane et al. 2009 4.900 1.413 2.131 7.669
SCZ Lieberman et al. 2005 15.000 2.800 9.513 20.487
SCZ McQuade et al. 2004 7.000 3.037 1.048 12.952
SCZ Saddichha et al. 2007 6.600 2.147 2.393 10.807
SCZ Vanelle et al. 2006 2.340 5.803 -9.033 13.713
SCZ Wu et al. 2006 -0.900 0.037 -0.972 -0.828
SCZ 5.629 2.254 1.212 10.046
Overall 2.146 0.413 1.336 2.956
-20.00 -10.00 0.00 10.00 20.00
Group by
DT
Study name Statistics for each study Mean and 95% CI
Standard Lower Upper
Mean error limit limit
Decreased
glucose level
Increased
glucose level
 
Figure 4 
 
 
Group by
DT
Study name Statistics for each study Mean and 95% CI
Standard Lower Upper
Mean error limit limit
BP McIntyre et al. Dec 2009 30.100 7.659 15.089 45.111
BP McIntyre et al. Nov  2009 35.400 7.019 21.642 49.158
BP NCT00510146 23.140 4.760 13.811 32.469
BP Tohen et al. 2008 17.800 7.629 2.848 32.752
BP 26.116 3.558 19.143 33.089
SCZ Breier et al. 2005 34.710 7.223 20.553 48.867
SCZ Lieberman et al. 2005 42.900 8.400 26.437 59.363
SCZ 38.192 5.477 27.458 48.926
Overall 29.700 2.983 23.852 35.547
-30.00 0.00 30.00 60.00
Decreased
triglycerides level
Increased
triglycerides level
 
Figure 5 
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BP McIntyre  et al. Nov 2010 0.103 0.058 0.176
BP McIntyre et al. April 2010 0.049 0.026 0.088
BP McIntyre et al. Dec 2009 0.087 0.057 0.131
BP McIntyre et al. Nov 2009 0.058 0.033 0.102
BP NCT00129220 0.029 0.009 0.085
BP NCT00510146 0.041 0.024 0.068
BP Tohen et al. 2006 0.046 0.024 0.087
BP Tohen et al. Dec 2003 0.099 0.064 0.148
BP 0.063 0.047 0.085
SCZ Alvarez et al. 2006 0.072 0.038 0.133
SCZ Beasley  et al. 1996 0.072 0.030 0.163
SCZ Bhowmick et al. 2010 0.012 0.001 0.167
SCZ Kane et al. 2009 0.146 0.109 0.192
SCZ Lecrubier et al. 2006 0.200 0.142 0.274
SCZ Lieberman et al. 2005 0.052 0.031 0.084
SCZ McQuade et al 2004 0.040 0.006 0.235
SCZ NCT00145496 0.058 0.034 0.097
SCZ NCT00645099 0.009 0.002 0.036
SCZ Sirota et al. 2006 0.143 0.047 0.361
SCZ Vanelle et al. 2006 0.125 0.053 0.267
SCZ 0.078 0.049 0.121
Overall 0.067 0.052 0.086
-0.25 0.00 0.25 0.50
Group by
DT
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper
rate limit limit
Less akathisia
incidence
More akathisia
incidence
 
Figure 6 
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Group by
DT
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper
rate limit limit
BP McIntyre et al. April 2010 0.068 0.041 0.112
BP McIntyre et al. Dec 2009 0.017 0.007 0.046
BP McIntyre et al. Nov 2009 0.011 0.003 0.041
BP McIntyre et al. Nov 2010 0.037 0.014 0.095
BP NCT00510146 0.009 0.003 0.027
BP Tohen et al. 2006 0.024 0.010 0.057
BP Tohen et al. Dec 2003 0.128 0.088 0.184
BP 0.031 0.014 0.068
SCZ Alvarez et al. 2006 0.289 0.216 0.376
SCZ Kane et al. 2009 0.043 0.024 0.074
SCZ Lecrubier et al. 2006 0.214 0.154 0.290
SCZ Lieberman et al. 2005 0.078 0.052 0.114
SCZ McQuade et al. 2004 0.120 0.039 0.313
SCZ Sirota et al. 2006 0.238 0.103 0.460
SCZ 0.139 0.070 0.255
Overall 0.071 0.042 0.118
-0.25 0.00 0.25 0.50
Less More
Parkinsonism incidence
 
Figure 7 
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Group by
DT
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper
rate limit limit
BP McIntyre et al. Nov. 2010 0.084 0.044 0.154
BP Tohen et al. 2006 0.040 0.021 0.075
BP Tohen et al. Dec 2003 0.184 0.139 0.239
BP Tohen et al. Nov. 2003 0.028 0.015 0.051
BP 0.067 0.024 0.172
SCZ Alvarez et al. 2006 0.258 0.188 0.344
SCZ Beasley et al. 1996 0.080 0.030 0.195
SCZ Bitter et al. 2004 0.079 0.036 0.165
SCZ Breier et al. 2005 0.089 0.055 0.140
SCZ Chan et al. 2010 0.143 0.061 0.300
SCZ Kane et al. 2009 0.214 0.170 0.265
SCZ Lieberman et al. 2005 0.074 0.051 0.108
SCZ Sirota et al. 2006 0.286 0.134 0.508
SCZ 0.137 0.088 0.208
Overall 0.121 0.081 0.178
-0.25 0.00 0.25 0.50
Less More
      Use of antiparkinson medication
 
Figure 8 
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3.1. Introduction 
Second generation antipsychotics (SGAs) have become a first-line medication in the 
treatment of psychotic disorders, such as schizophrenia and schizoaffective disorders 
(Lublin et al., 2009, Rummel-Kluge et al., 2010b) and a serious consideration in the 
treatment of several affective disorders (Bowden et al., 2005, Tohen and Vieta, 2009). 
Several studies have proposed SGA monotherapy or combination therapy in controlled 
trials, comparing them to placebo or to first-generation antipsychotics (FGAs) (Chen et al., 
2011, Correll et al., 2010, Komossa et al., 2010, Leucht et al., 2009b). However, the 
treatment with SGAs has been associated with concerns about metabolic side effects, which 
can induce long-term consequences such as metabolic syndrome, diabetes mellitus and 
cardiovascular diseases (CVD). Patients with severe mental diseases are 2-3 times more at 
risk for obesity, metabolic syndrome, and related morbidity and mortality compared to 
general population (Correll et al., 2010, Holt et al., 2010). 
 Factors that affect patients with severe mental illnesses and contribute to metabolic 
syndrome and diabetes mellitus include genetic predisposition to certain pathologies such 
as weight gain, diabetes mellitus and lipid abnormalities (Bellivier, 2005, Gough and 
O'Donovan, 2005, Hasnain et al., 2009); sedentary life style and poor diet (Meyer and 
Stahl, 2009, Phelan et al., 2001); high levels of smoking, alcohol intake and drug abuse 
(Green et al., 2007, Regier et al., 1990); limited access to regular health care services 
(Chacon et al., 2011); and potential metabolic adverse events which occur during 
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antipsychotic treatment (Haddad and Sharma, 2007, Meyer and Stahl, 2009, Stahl et al., 
2009).  
 An increased number of evidences have suggested that certain SGAs are associated 
with increased risk of metabolic complications such as obesity, glucose intolerance and 
dyslipidemia, which are risk factors for developing diabetes mellitus, metabolic syndrome, 
CVD and premature death. Thus, the physical health of mental disorder patients is further 
influenced by SGAs treatment. The SGAs side effects on physical health have become an 
important issue in mental illnesses’ treatment (De Hert et al., 2011b). These side effects are 
especially important in vulnerable population, such as drug-naïve first-episode patients, 
children and adolescents (De Hert et al., 2011c).  Literature findings revealed that 
individual SGAs differ in their liability to induce metabolic disturbances (Haddad, 2005, 
Newcomer, 2005, Allison et al., 1999). Generally, clozapine and olanzapine are known to 
be associated with the highest risk of clinically significant weight gain, followed by 
quetiapine, risperidone and sertindole (Allison et al., 1999, Haddad, 2005, Newcomer, 
2005). Amisulpride, ziprasidone and aripiprazole have the lowest risk for clinically 
significant weight gain (Allison et al., 1999, Haddad, 2005, Newcomer, 2005).  
 Furthermore, based on the published data olanzapine and clozapine also increase the 
risk of diabetes and dyslipidemia. The findings about quetiapine and risperidone are 
controversial and need more investigations, while amisulpride, ziprasidone and aripiprazole 
do not seem to significantly change blood glucose levels or lipid profiles (De Hert et al., 
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2011c, Haddad, 2005, Newcomer, 2005, Rummel-Kluge et al., 2010b, De Hert et al., 
2011a, Newcomer and Haupt, 2006). 
 Extrapyramidal symptoms (EPS) including dystonia, parkinsonism and akathisia, are 
other common side effects associated with antipsychotic treatment (Cavazzoni et al., 2006). 
The incidence of movement disorders related to the use of antipsychotics is thought to 
occur due to D2 receptors blockade in the striatum. The drugs with higher affinity for D2 
receptors cause higher rate of EPS (Balestrieri et al., 2000).  Although, SGAs have a more 
favourable EPS profile than FGAs (Leucht et al., 2009a, Miller et al., 1998), studies have 
shown that EPS, including akathisia (Kane et al., 2009a) and tardive dyskinesia (Kane, 
2004), are also observed with SGAs. Acute development of EPS in several studies has been 
identified as an important risk factor for later development of tardive dyskinesia in 
schizophrenia patients (Muscettola et al., 1999, Tenback et al., 2006). 
 While some studies have shown the similar risk of SGAs-induced EPS in bipolar 
patients (BP) and schizophrenia, other studies have reported more vulnerability to 
movement disorders in bipolar patients (Cavazzoni et al., 2006, Gao et al., 2008, Nasrallah 
et al., 1988).  
 Schizophrenia and affective disorders both are polygenic and multi-factorial complex 
disorders in which a myriad of different genes are potentially involved. Even though BP 
and SCZ differ in neurobiology and phenomenology (McDonald et al., 2004, Muir et al., 
2001, Murray et al., 2004), these disorders share some genetic features (Huang et al., 2010, 
Park et al., 2004, Peerbooms et al., 2010, Purcell et al., 2009). Although the 
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pathophysiology of both disorders remains unclear, in recent years, the investigation of the 
factors which contribute to the SGA’s tolerability profiles in AD and SCZ has just emerged 
(Stahl et al., 2009, van Winkel et al., 2008).
 
 Based on broad SGAs prescriptions for different diagnoses in psychiatry, it would be 
interesting to see whether the side effects have a different expression and severity 
according to phenotype. In a previous article, we examined the potential difference in 
olanzapine-induced metabolic side effects between SCZ and AD patients, in which we 
found more vulnerability in SCZ patients regarding these side effects. However, only the 
weight gain was significantly higher in schizophrenic patients compared to AD patients 
(Moteshafi et al., 2012). As only olanzapine side effects were considered in our prior work 
(Moteshafi et al., 2012), the current meta-analysis extends our earlier work to other most 
frequently prescribed SGAs: quetiapine, risperidone, ziprasidone and aripiprazole. This 
study aimed to compare the tolerability and safety profiles of these SGAs in different 
diseases, and in particular to investigate whether the side effects have a different expression 
and severity according to phenotype between SCZ and AD patients groups.  
 A difference in severity of side effects could mean that a phenotype per se influences a 
medication’s tolerability profile. We hypothesized that phenotype of disease may affect 
induction and severity of side effects. With the increasing use of SGAs in psychiatry, this 
investigation is valuable, not only to inform clinicians, but also to provide clues to the 
pathophysiology of schizophrenia-spectrum and affective disorders. 
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3.2. Methods 
3.2.1. Data sources and search strategy 
Systematic reviews of the literature on four antipsychotics (quetiapine, risperidone, 
ziprasidone and aripiprazole) in the treatment of schizophrenia and affective disorders that 
reported randomized controlled trials (RCTs) were performed. The keywords used for the 
search were quetiapine, risperidone, ziprasidone, or aripiprazole in conjunction with 
schizophrenia or affective disorder, bipolar disorder, major depression, bipolar mania, 
unipolar depression. The search engines were PsycINFO (1967-2010), PubMed 
(MEDLINE), EMBASE (1980-2010) and clinicaltrials.gov website. There were no 
limitations on language. A hand search of published review articles, as well as cross-
referencing, was carried out to gather further data. It is important to mention that at this 
stage, we could not find any article that reports SGAs side effects for both schizophrenia 
and affective disorder patients; therefore, we searched for articles that report SGAs side 
effects in either SCZ or AD groups; the results were then compared together. Authors of the 
selected studies that met inclusion criteria were contacted to provide unreported or 
additional data. Two reporters independently checked all reports for inclusion and 
exclusion criteria. 
3.2.1.1. Inclusion criteria 
Studies were searched for two diagnostic groups: affective disorders and schizophrenia. 
Inclusion criteria were studies that contained (1) adults patients (18-65 years old) which 
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had a diagnostic of schizophrenia or affective disorders such as, major depression, bipolar 
mania, or bipolar depression; (2)  randomized controlled trials (open-label or double-blind); 
(3) oral monotherapy treatment with quetiapine, risperidone, ziprasidone, or aripiprazole; 
(4) fixed and flexible-dose studies with a duration of three weeks or longer; and (5) 
reported data on metabolic or extrapyramidal side effects. 
3.2.1.2. Exclusion criteria  
Trials in both groups were left out if they contained (1) combination therapy of any agent 
with another medication such as anti-manic or antidepressant; (2) other psychotic diagnoses 
such as schizoaffective or schizophreniform disorders; (3) incomplete or unavailable data 
even after contacting author; (4) study groups of children or adolescents; (5) non-
randomized design; or (6) treatment with depot antipsychotics. 
3.2.2. Data extractions and outcome parameters 
Two reviewers (H.M. and E.S.) independently checked abstracts and chose related articles, 
then one reviewer (H.M.) extracted data while checking the inclusion criteria. Trial 
abstracts were screened initially and then in the second step full-texts were reviewed. Data 
from schizophrenia and affective disorders group were compared. The data extractions 
were separated along two dimensions: (a) clinically important metabolic side effects such 
as change of weight, blood glucose and cholesterol levels. Weight change was reported as 
the change in kilograms from baseline to endpoint; the changes in other metabolic 
parameters were defined as the change from baseline to endpoint in mg/dl. (b) some EPS 
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related adverse events (such as akathisia and parkinsonism), as well as the use of 
antiparkinson medication for treating EPS were checked. The outcome variable was 
incidence of EPS related side effects, as measured by treatment-emergent adverse event 
data. 
3.2.3. Meta-analytic calculations  
Using Comprehensive Meta-Analysis (CMA) software version 2.2.05 (Borenstein et al., 
2010), effect size estimates for each side effect was calculated. For each group of subjects, 
AD and SCZ patients, effect size estimates were calculated from (i) mean and standard 
deviation of metabolic side effects or (ii) events rates for extrapyramidal side effects.  
Continuous outcomes (metabolic side effects) were analyzed by estimating means and 
confidence intervals for each group of subjects: schizophrenia and affective disorders. Also, 
dichotomous outcomes (extrapyramidal side effects) were analyzed by estimating event rate 
and confidence intervals for each group of subjects. The effect size estimates for all studies 
in each patients’ group (SCZ or AD) were pooled together to yield an overall effect size 
estimate for each group. Then, CMA was used to compare the point estimate of each group 
to see whether the difference between the points was significant or not. The level of 
significance for the effect size estimates was set at p=0.05.   
 For all analyses, effect size estimates were pooled with the random-effects model, 
which is more strict than fixed-effects model and permits population-level inferences as 
well (DerSimonian and Laird, 1986). Meanwhile we assessed the heterogeneity of study 
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with the I-squared statistic, supposing that I
2
 statistics greater than 50% proposed 
considerable heterogeneity.  
3.2.3.1. Sub-analyses and addressing potential confounding factors 
Sub-analyses, including between-group differences, were carried out for potential 
confounding factors in age, sex ratio, and medication daily dose. The effects of treatment 
duration on the results were examined by performing subgroup analyses including short-
term (less than 12 weeks) and longer term studies (more than 12 weeks), separately. We 
also performed mixed-effects meta-regression to investigate whether percentage of male 
patients involved in studies were correlated with the differences in effect size and to explain 
potential heterogeneity. 
3.3. Results 
3.3.1. Literature searching results 
3615 abstracts were identified initially in which 1732 were related to the SCZ group and 
1883 to the AD group. Among these, 3535 were discarded on the basis of duplication or 
evaluating abstract and article, according to the following criteria: (1) type of article/study 
(e.g., case study, review, letter to the editor and crossover study); (2) type of population 
(e.g., non randomized, nonschizophrenia patients, age range); (3) treatment type (e.g., 
combination therapy or depot administration); (4) incomplete or non available data. As a 
result, 80 studies (n=14319) were accepted for both groups: for SCZ patients N=47, 
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n=7700
2
 and for AD group N=33, n=6619. SCZ group articles contained 15 for quetiapine, 
9 for aripiprazole, 8 for ziprasidone and 15 for risperidone. AD group articles contained 16 
for quetiapine, 9 for aripiprazole, 4 for ziprasidone and 4 for risperidone. 
 It should be mentioned that for the AD group we could only find articles related to the 
bipolar disorder (BP); we could not find related studies on other affective disorders, 
considering our inclusion criteria. More information on the sorting process in each group is 
shown in Figures 1 and 2. In addition, Tables 1 and 2 provide details of demographic 
characteristics among studies included in the meta-analysis.   
3.3.2. Outcome results 
3.3.2.1. First outcome: metabolic changes 
(a)Weight gain 
In quetiapine treatment, 10 studies for the SCZ (n=1683) and 12 for the BP group (n=3411) 
were reviewed for weight changes. Even though the increase from baseline was more in 
SCZ group, there was no statistically significant difference between the two groups (1.72 
kg vs. 1.15 kg; p=0.108).  
 For aripiprazole treatment, four studies in the SCZ (n=1493) and six in the BP group 
(n=844) were checked. The analysis revealed a slight decrease from baseline in the SCZ 
group and an increase in weight from baseline for the BP group; however, there was no 
                                                 
2 “N” refers to the number of articles whereas “n” is the number of patients. 
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statistically significant difference between the two groups (-0.4 kg vs. 0.49 kg, respectively; 
p=0.109). 
 For risperidone, 13 studies in the SCZ (n=1278) and two in the BP group (n=272) were 
examined. Even though the analysis revealed an increase from baseline in both groups, 
there was no statistically significant difference between the two disorders (1.32 kg vs. 1.55 
kg, for SCZ and BP, respectively; p=0.486). 
 Despite checking all articles for ziprasidone, we could not find enough data related to 
its monotherapy and metabolic side effects. Therefore, we were not able to compare any 
metabolic parameters for this agent. In addition, for risperidone treatment the data was only 
available on weight changes. Thus, the rest of metabolic changes will only be reported for 
quetiapine and aripiprazole treatment.  
(b) Cholesterol change 
Quetiapine increased blood cholesterol levels to 8.05 mg/dl in SCZ group (N=4, n=1473) 
and decreased cholesterol level in BP group (N=7, n=2433) to 2.8 mg/dl. The SCZ group 
showed significantly more cholesterol increase than the BP group (p=0.000). Details are 
shown in Figure 3. 
 For aripiprazole, two studies in the SCZ (n=393) and two in the BP group (n=360) 
were examined for changes in blood cholesterol levels. Aripiprazole decreased the levels of 
cholesterol in both groups. However, the difference between the two groups was not 
significant (-5.76 vs. -3.52 mg/dl, for SCZ and BP, respectively; p=0.629). 
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(c) Glucose change 
For quetiapine, five studies (n=1553) in the SCZ group and ten (n= 3214) in the BP group 
were checked for changes in blood glucose levels. Quetiapine increased blood glucose 
levels similarly in both groups. (4.01 vs. 3.85 mg/dl, for SCZ and BP, respectively; 
p=0.927).  
 Aripiprazole increased blood glucose levels in the SCZ (N=2, n=441) and the BP 
groups (N=2, n=360). Mean change was 2.02 mg/dl in the SCZ vs. 3.51 mg/dl in the BP 
groups, with no significant difference between the two groups (p=0.490). 
(d) Triglyceride change 
For quetiapine, four studies (n=1269) in the SCZ and seven studies (n= 2342) in the BP 
group were examined for changes in blood triglyceride levels. The analysis revealed an 
increase in triglyceride levels in both groups; however, the difference between the groups 
was non-significant (17.57 mg/dl vs. 7.93 mg/dl, for SCZ and AD, respectively; p=0.099). 
(e) LDL change 
Quetiapine increased mean LDL levels in SCZ group (N=3, n=1001) up to 5.00 mg/dl and 
decreased LDL level in BP group (N=7, n=2427) to 2.78 mg/dl. This change on LDL levels 
was significant between the two groups (p =0.000). Details are shown in Figure 4. 
(f) HDL change 
We could not find enough studies to compare HDL changes among treatment groups. 
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3.3.2.2. Second outcome measure: extrapyramidal side effects 
As known, SGAs extrapyramidal side effects are less than those of conventional 
antipsychotics. In our study, as well, EPS-related adverse event rates and their intensity 
were low in both groups; however, there were significant differences in the frequency of 
some EPS associated with SGAs treatment between the two groups. 
(a) Incidence of akathisia 
The akathisia event rate did not differ significantly between the two groups for quetiapine 
treatment. Based on five articles included in the BP group (n=961), the event rate was 
6.4%; according to six articles in the SCZ group (n=1095), the incidence of akathisia was 
4.8% (p=0.463). 
 Patients treated with aripiprazole in the BP group (N=8, n=1307) showed more 
akathisia incidence compared to SCZ patients (N=8, n=2264), 14.6% vs. 5.4% respectively. 
This difference was significant (p=0.001). Details are shown in Figure 5. 
 For ziprasidone treatment 10 studies (n=1459), four studies (n=584) in the BP and six 
studies (n= 875) in the SCZ group, were checked. Even though akathisia incidence was 
higher in the BP group compared to the SCZ group, 13.2% vs. 7.7% respectively, this 
difference was not significant (p=0.065).  
 For risperidone treatment not enough data was available to conduct any comparison 
between the two groups, in the incidence of akathisia.  
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(b) Incidence of parkinsonism 
The incidence of parkinsonism did not differ significantly between the two groups for 
quetiapine treatment. Based on eleven articles included in the BP group (n=3134), the event 
rate was 7.5%; according to eight articles in the SCZ group (n=1870), the incidence of 
parkinsonism was 9.6% (p=0.326). 
 In aripiprazole treatment, there was no significant difference between the SCZ (N=7, 
n=1979) and the BP groups (N=4, n=701). The event rate was 6.7% vs. 10.4%, for SCZ and 
BP, respectively (p=0.069).  
 The incidence of parkinsonism was not significantly different between the two groups 
of patients with risperidone treatment. Based on two articles included in the BP group 
(n=300), and seven articles in the SCZ group (n=1194), the event rate was 23.4% vs. 
29.3%, respectively (p=0.4).  
 In ziprasidone treatment, the difference in incidence of parkinsonism was not 
significant between the SCZ (N=6, n=868) and the BP groups (N=3, n=444). The event rate 
was 5.7% vs. 15.7%, for SCZ and BP, respectively (p=0.902).  
(c) Antiparkinson medication use  
Quetiapine treatment was not associated with significant difference in the use of 
antiparkinson medication between the two groups. According to four articles included in 
the BP group (n=489), the event rate was 5.1%; in ten articles in the SCZ group (n=2146), 
the use of such medication was 7.7% (p=0.455).  
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 In aripiprazole treatment, there was no significant difference in the use of antiparkinson 
medication between the SCZ (N=6, n=1958) and the BP groups (N=4, n=603). The event 
rate was 16.7% vs. 17.4%, for SCZ and BP, respectively (p=0.905).  
 Antiparkinson medication use differed between the two groups for risperidone 
treatment. SCZ patients (N=8, n=1097) used less antiparkinson medication compared to BP 
patients’ group (N=2, n=280), 23.1% vs. 28.3% respectively. However this difference was 
not significant (p=0.575).  
 In ziprasidone treatment, there was no significant difference in the use of antiparkinson 
medication between SCZ (N=7, n=1093) and BP groups (N=2, n=317). The event rate was 
21.1% vs. 35.3%, for SCZ and BP, respectively (p=0.927). 
3.3.2.3. Heterogeneity 
Heterogeneity of all outcomes (metabolic and extrapyramidal) were explored by I
2
 statistic; 
they were all heterogeneous (I
2
>50%). Sub-analyses were assessed to determine possible 
sources of heterogeneity in the results. 
3.3.3. Sub-analyses  
3.3.3.1. Age 
All studies reported mean age and standard deviation (SD) of participants; no difference 
was observed between the two groups of patients in all four treatment groups.  See Tables 1 
and 2 for more information on demographic characteristics among studies included in the 
meta-analysis. 
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3.3.3.2. Sex ratio 
Number of male and female patients was also reported in all studies. Significantly more 
males participated in the studies of SCZ group studies compared to the BP groups in all 
treatment groups, except for risperidone treatment group. Considering the significant 
difference in male percentage between SCZ and BP patients’ groups, this variable was 
included in the statistical analysis as a regressor.  
 By performing a meta-regression on akathisia incidence in aripiprazole treatment, the 
percentage of male gender was not a significant moderator to explain the heterogeneity in 
BP and SCZ patients’ groups.  
 When we performed meta-regression analyses to find the source of heterogeneity in 
quetiapine treatment, we only found that the male percentage of BP patients’ group could 
be a significant moderator in explaining the heterogeneity of LDL and Cholesterol. In the 
SCZ group no meaningful regression could be done due to small number of studies; 
however, because of the significant difference on the sex ratio between BP and SCZ, the 
sex ratio could be a source of heterogeneity.  
3.3.3.3. Dose  
Based on studies in BP and SCZ groups which specified mean daily dose, no difference 
was observed between the two groups in all five treatment types. 
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3.3.3.4. Treatment duration 
 We stratified the studies based on treatment duration. The results of short-term studies 
(between 3 and 12 weeks) for quetiapine treatment remained the same as the main analysis. 
It means increases in cholesterol and LDL levels stayed significantly higher for SCZ 
patients compared to AD patient in short-term studies. In addition, akathisia incidence was 
considerably higher in the BP group compared to the SCZ group. The other parameters 
continued to display no significant difference, similar to the results of the main analysis.   
 In aripiprazole treatment, stratification of studies by treatment duration, showed 
significantly more akathisia and parkinsonism incidence in BP group compared to SCZ. It 
should be noted that parkinsonism incidence was not significantly different before 
stratification. 
        For risperidone and ziprasidone treatment, all parameters displayed no significant 
difference, as in the main analysis. 
 For studies more than 12 weeks, we did not find enough data to check in the BP group 
in all treatment types. 
3.4. Discussion  
In this chapter we examined the difference in frequency and intensity of metabolic and 
extrapyramidal side effects of four common atypical antipsychotics in SCZ and AD 
patients. In our previous article (Moteshafi et al., 2012), we also presented the first meta-
analysis comparing the potential difference in olanzapine-induced side effects between SCZ 
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and AD patients. Based on our hypothesis, there is a difference between SCZ and AD 
patients for metabolic and extrapyramidal side effects. Recently, atypical antipsychotic 
agents have been linked to several forms of morbidity, including obesity, hyperlipidemia, 
and type-2 diabetes mellitus, which predict metabolic syndrome, cardiovascular morbidity 
and malignancy (De Hert et al., 2011a, Henderson et al., 2005, Newcomer et al., 2002). 
Metabolic syndrome is a significant public health problem in patients with severe mental 
illnesses and particularly schizophrenia. The mechanisms responsible for an association 
between mental disorder, antipsychotic treatment and metabolic syndrome remain elusive 
(Bond et al., 2010). According to different phenotypes of these mental illnesses and 
frequent use of SGAs to treat them, studying the degree of sensitivity and tolerability of 
SGAs in AD and SCZ patients seems essential.  
 In general, as many studies have indicated, atypical antipsychotics do not form a 
homogenous group causing similar adverse events; therefore, some SGAs can lead to 
metabolic disturbances, while the others may not; our findings are consistent with other 
studies in this regard (Gao et al., 2008, Rummel-Kluge et al., 2010a, Rummel-Kluge et al., 
2010b, Simon et al., 2009). 
 As in our previous article on olanzapine-induced side effects (Moteshafi et al., 2012), 
we examined the metabolic side effects (weight gain, blood glucose, cholesterol, LDL and 
triglyceride levels) of the other four most commonly prescribed SGAs—quetiapine, 
ziprasidone, aripiprazole and risperidone—as our first outcome. We found that, olanzapine 
(Moteshafi et al., 2012) and quetiapine, as also mentioned in the other studies (Rummel-
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Kluge et al., 2010b, Simon et al., 2009), are associated with more changes in metabolic 
parameters relative to other SGAs. In a meta-analysis comparing all SGAs head-to-head, 
weight gain was seen significantly more with clozapine and olanzapine treatment than with 
other antipsychotics (Rummel-Kluge et al., 2010b). Moreover, one study indicated that 
olanzapine treatment resulted in the most weight gain followed by quetiapine and 
risperidone (Simon et al., 2009). Aripiprazole and ziprasidone caused the lowest risk for 
clinical weight gain (De Hert et al., 2009, De Hert et al., 2011c). In our prior meta-analysis 
(Moteshafi et al., 2012), olanzapine induced significantly more weight gain in SCZ patients 
compared to the AD group. Based on our present meta-analysis, with quetiapine treatment, 
SCZ patients gained more weight; however, the difference was not significant.  
 The mechanism of SGA-induced weight gain is still unexplained. Several hypotheses 
consider a complex interaction of neurotransmitters, hormones and cytokines in appetite 
and weight gain controls (Srivastava et al., 2008). Some factors such as a high affinity of 
these medications to serotonin (5-HT2C, 5-HT2A, 5-HT6) , dopamine (D2 and D3), histamine 
(H1), adrenergic (α1 and α2) and muscarinic (M1, M2, M3 and M5) receptors could be 
responsible for weight gain (Allison et al., 1999, Czobor et al., 2002, Haddad, 2005, 
McQuade et al., 2004, Reynolds et al., 2005). Higher affinity to H1, 5-HT2A and 5-HT2C 
receptors is associated with hunger and may lead to increased food intake (Correll et al., 
2011, De Hert et al., 2011c). Furthermore, the blockade of H1 and α1 receptors can induce 
sedation, which may lead to immobility and weight gain (Czobor et al., 2002). Genetic data 
also propose a role of leptin receptor activity, G-protein signaling, cannabinoid receptor 
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activity and promelanin-concentrating hormone signaling in the SGAs weight gain (Correll 
et al., 2011, De Hert et al., 2011c).   
 We also examined the mean changes in glucose levels for quetiapine and aripiprazole. 
Even though we found increases of glucose levels from baseline for these two SGAs, the 
difference between BP and SCZ was not significant. This outcome was similar to 
olanzapine-induced glucose changes (Moteshafi et al., 2012). The mechanism underlying 
the effect of some SGAs, especially olanzapine, on glucose levels and insulin resistance 
remains unclear. However, there is some indication that the long-term use of olanzapine 
may decrease insulin secretion, which may lead to hyperglycemia (Nakamura and 
Nagamine, 2010). A proposed mechanism for hyperglycemia is related to the drug’s 
affinity for the H1, M3 and 5-HT2C receptors, which is correlated with an increased risk of 
diabetes (Nasrallah, 2008). Another possible mechanism for the increase of insulin 
resistance with olanzapine treatment could be impairing the ability of insulin to stimulate 
glucose uptake into peripheral tissues such as skeletal muscle and adipose tissue. 
  There is recent evidence indicating that polymorphism in 5-HT2A and 5-HT2C receptor 
coding genes, HTR2A and HTR2C, seems to be associated with development of metabolic 
abnormalities such as C-peptide and insulin elevation during olanzapine and clozapine 
treatment (Bai et al., 2011, Gunes et al., 2009, Melkersson et al., 2010).  
 The last metabolic factor we looked at was mean variations in lipid parameters. Lipid 
profile in our meta-analysis showed that quetiapine increased significantly the mean level 
of total cholesterol and LDL in the SCZ group. Quetiapine contributed to more triglyceride 
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increases for SCZ patients compared to the BP group; however, this difference was not 
significant. It is noteworthy that based on the results reported by Zhornitsky et al. (2011), 
quetiapine may associate with more LDL and cholesterol changes in the SCZ group 
compared to other mental disorders, which is in agreement with our findings. In this 
systematic review (Zhornitsky et al., 2011), quetiapine efficacy and tolerability profiles 
across psychotic disorders were evaluated. The findings suggest a possible interaction 
between schizophrenia genes and quetiapine treatment in increasing metabolic disturbances 
(Stahl et al., 2009). 
 Aripiprazole treatment decreased the cholesterol levels in SCZ patients, and was 
associated with a small increase in cholesterol levels for AD group, a group difference 
which is also not statistically significant. Due to lack of available data, we could not 
evaluate triglyceride and LDL levels for aripiprazole treatment. 
 As mentioned in our prior article (Moteshafi et al., 2012), olanzapine treatment 
increased blood cholesterol and triglycerides levels in both groups and induced more 
changes in SCZ patients compared to BP patients. However, the differences between two 
patients groups were not significant, for both blood cholesterol and triglycerides levels.  
 Some SGAs are associated with dyslipidemia, including increased levels of LDL, total 
cholesterol and triglycerides, which can result in CVD (Casey, 2004). At present, the exact 
mechanism underlying changes in lipids due to certain SGAs treatment is unknown. A 
plausible mechanism depends on the SGAs role in lipogenesis increase, lipolysis reduction, 
and enhancement of antilipolytic insulin’s effect in adipocytes, which may result in lipid 
  
 
96
accumulation (Albaugh et al., 2011, Chaggar et al., 2011). In addition, several hypotheses 
have been proposed regarding biological factors such as weight gain, dietary changes and 
the development of glucose intolerance to explain the high frequency of dyslipidemia with 
specific antipsychotic medications (Meyer, 2001). Moreover, Ferno and his colleagues 
(Ferno et al., 2005) indicated that some antipsychotics upregulate the genes which are 
involved in biosynthesis of cholesterol and fatty acids. In their findings, first or second 
generation antipsychotic agents stimulate cellular lipogenesis via a direct activation of the 
sterol regulatory element binding protein (SREBP).   
 Our meta-regressions showed that male percentage was a significant moderator in the 
BP group and could explain some of the heterogeneity. In studies with a higher proportion 
of male participants, more cholesterol and LDL changes happened in the BP group. The 
number of studies for the SCZ group was too small for a meta-regression. In the quetiapine 
treatment group, we conducted our meta-analysis for the short-term treatment studies. The 
results of cholesterol and LDL levels stayed the same as our main analysis, which means 
significantly more changes in the SCZ group compared to BP. 
 The biological mechanism underlying different metabolic disturbances between SCZ 
and AD patients in SGAs treatment is not yet clear. Some authors have indicated possible 
inherent genetic vulnerability to metabolic irregularity in schizophrenia patients (Dasgupta 
et al., 2010, Spelman et al., 2007, Venkatasubramanian et al., 2007). They believe that 
schizophrenia may be an independent and important risk factor for both diabetes and 
impaired glucose tolerance; although, some other studies are not in line with this suggestion 
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(Arranz et al., 2004, Zhang et al., 2004). Other studies have described that stress, 
particularly dysfunction of the hypothalamo-pituitary-adrenal (HPA) axis activity and 
therefore increases in cortisol and DHEA (dehydroepiandrosterone) levels, in both acute 
phases of chronic schizophrenia and bipolar disorder patients may disturb metabolic 
parameters (Gallagher et al., 2007, Steen et al., 2011). In some reports, schizophrenic 
patients showed more sensitivity to daily stress than bipolar patients (Myin-Germeys et al., 
2003). In addition, the polymorphism of brain-derived neurotrophic factor (BDNF) gene 
was recently found to be associated with antipsychotic-induced weight gain in patients with 
chronic schizophrenia (Zhang et al., 2008). 
 Furthermore, the duration of treatment or prior antipsychotic medication might 
influence the metabolic results. BP patients have a better psychosocial functioning profile, 
and most of them take less antipsychotic medications compared to SCZ patients. Sedentary 
lifestyle, poor diet, smoking and drug abuse, and finally antipsychotic treatment are all 
important factors which may affect weight gain and other metabolic parameters in 
schizophrenic patients.  
 Putting all these findings together may help to conclude that the patients with 
schizophrenia might be more prone to obesity and other metabolic disturbances compared 
to other mental disorders.  
 As our second outcome, we examined extrapyramidal symptoms related to SGAs 
treatment for different mental illnesses.  Based on our results, akathisia occurred more 
frequently in the AD group versus SCZ group in relation to quetiapine, ziprasidone and 
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aripiprazole treatment. However, this difference in akathisia incidence was significant only 
with aripiprazole treatment.   
 In our results, incidence of parkinsonism was higher in the AD group compared to the 
SCZ group for ziprasidone and aripiprazole treatment; however, the differences between 
the two disorders were not statistically significant.   
  Antiparkinson medication use was also checked and no significant difference was 
found between SCZ and AD.  However, in the AD group, antiparkinson medication was 
used more often when the patients were under ziprasidone and aripiprazole treatment.  
 Some reports in the literature suggest that bipolar disorder patients, especially in the 
depression phase, are more likely to develop EPS than SCZ patients (Gao et al., 2008, 
Nasrallah et al., 1988). They mentioned that each atypical antipsychotic has a different 
liability, and based on their review, haloperidol, aripiprazole, risperidone and ziprasidone 
treatments were associated with more overall EPS in BP patients compared to the SCZ 
group.  
 We performed meta-regression to find the source of heterogeneity in aripiprazole 
treatment. Akathisia incidence showed no relationship with the male percentage in BP 
patients. So, male percentage was not a significant moderator to explain the heterogeneity.  
 Furthermore, as mentioned earlier, when the studies were stratified based on treatment 
duration, in studies less than 12 weeks, significantly more akathisia incidence was observed 
in the BP patients compared to the SCZ group in aripiprazole and quetiapine treatments.  
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 Some limitations affect this meta-analysis, which are explained in detail in (Moteshafi 
et al., 2012). These limitations may confound our results and may explain the heterogeneity 
detected in the analysis.  
 The result of this meta-analysis proposes that factors such as life style and disease 
phenotype may contribute to more susceptibility to some SGAs-induced metabolic side 
effects in the SCZ group. Genetic polymorphism may be an important factor that 
contributes to metabolic side effects of SGAs between SCZ and AD patients. In addition to 
a genetic predisposition for metabolic syndromes among schizophrenic patients, lifestyle 
risk factors such as stress, poor diet, lack of exercise and smoking are more common in 
schizophrenic patients (Bai et al., 2011, Liou et al., 2012). 
 Patients with severe mental illnesses should be monitored regularly, especially for 
metabolic issues induced by SGAs therapy. 
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Table legends 
Table 1: Demographic characteristics among schizophrenia studies included in the meta- 
analysis 
Table 2: Demographic characteristics among affective disorders studies included in the 
meta-analysis 
 
Tables 
Table 1 
Medication/Study Age (mean± 
SD), y 
Dose(mean± 
SD),mg/day 
Treatment  
duration, w 
Male/Female, N 
Quetiapine     
Riedel et al. 2005 30.6±10.9 589.7 12 15/7,22 
Riedel et al. 2007  36.69±11.71 586.8±169.1 8 10/6,16 
Arvantis et al.1997 37.4±9.4 75, 150, 300, 
600,750 
6 191/67,258 
Borison er al. 1996 36±9 307 6 48/6,52 
Kahn et al. 2007 34.3±10 400, 600,800 
XR/400IR 
6 277/181,458 
Lieberman et al. 2005 40.9±11.2 543.4 72 255/82,337 
Lindermayer et al. 2008 39.2±10.3 300,600,800XR/30
0,600IR 
6 310/110,420 
Peuskens et al. 2007 37 674 52 49/35,84 
Small et al. 1997 36.5±9 250,750 6 139/51,190 
Zhong et al. 2006 40.2±10.8 525±231 8 260/78,338 
Conley et al. 2005 43.7±5.9 463.6±50.5 12 10/2,12 
Atmaca et al. 2003 30.1±8.4 535.7±110.5 6 6/8,14 
Buckley et al. 2004 39±11.1 600 8 38/16,54 
Cpolov et al. 2000 37±10 455±174 6 158/63,221 
Sirota et al. 2006 38.3±12.2 637.2±121.1 12 15/4,19 
     
Aripiprazole     
Kolotkin et al. 2008 38.1±10.8 10-30 26 165/113,278 
Cutler et al. 2006 40.5 2, 5, 10 6 216/63,279 
Kasper et al. 2003 37.3±11.7 29.01 52 511/350,861 
Kerwin et al. 2007 38.1±10.8 18.7 26 169/115,284 
Kane et al. 2007 42.6±12.4 28.8 6 114/40,153 
McQuade et al. 2004 38.6±10.6 25.1 26 114/42,156 
Pigott et al. 2003 42.2 15 26 84/71,155 
Kane et al. 2009 37.3±10.4 19.3 28 190/95,285 
Chrzanowski et al.2006 41.7±12.2 15-30 52 59/45,104 
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Ziprasidone      
Breier et al. 2005 38.2±12.1 115.96±39.91 28 172/99,271 
Sacchetti et al.2009 41.6±10.2 142±23 18 52/21,73 
Lieberman et al. 2005 40.1±11 112.8 78 129/56,185 
Kane et al. 2006 35.6±9.5 153.8±17 6 103/49,152 
Olié et al. 2006 39.4 118 12 41/19,60 
Arato et al. 2002 50 40, 80,160 52 144/63,207 
Hirsch et al. 2002 39.2 116.5 28 92/56,148 
Cutler et al. 2008 40±9.9 160 4 113/36,149 
     
Risperidone     
Liberman et al. 2005 40.6±11.3 3.9 72 115/46, 161 
Yang et al. 2010 35.97±10.15 4.09±1.56 8 194/87, 281 
Hwang et al. 2003 34.1±9.9 6.88±1.54 6 25/11, 36 
Zhong et al. 2006 39.6±10.8 6±1.8 8 20/18, 38 
Riedel et al. 2005 39.3±12.3 4.9 6 94/46, 140 
Riedel et al. 2007  39.6±12.4 5.1±1.4 12 16/19, 35 
Dollfus et al. 2005 39.6±10 6±2.1 8 11/6, 17 
Sechter et al. 2002 38.4±10.7 6.92±2.14 24 14/10, 24 
Bondolfi et al. 1998 38.3±12.9 6.4±2.1 8 244/92, 336 
Azorin et al.  2001 39.5±11.3 9±4 12 17/4, 21 
Atmaca et al. 2003 27.9±7.8 6.7±3.6 6 11/18, 29 
Saddichha et al.  2007 26.7±6.3 4.5±1.2 6 46/30, 76 
Peuskens et al. 1999 37±12 8 8 180/97, 277 
Conley et al. 2005 46.3±8.7 4.31±0.63 12 85/39, 124 
Lin et al. 2010 38 4 6 24/18,42 
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Table 2 
Medication/Study Age (mean± SD), 
y 
Dose (mean± 
SD), mg/day 
Treatment  
duration, w 
Male/Female, 
N 
Quetiapine     
McElroy et al. 2010 b 38.4 300,600 8 179/282,461 
Bowden et al.  2005 38 584 12 60/47,107 
Endicott et al.  2008 37.1±11.1 300,600 8 308/390,698 
Altamura et al. 2003 50.6±8 157.7±157.6 52 5/9,14 
McElroy et al. 2010 a 34±11.2 232 8 9/10,19 
Weisler et al. 2009 40.9±11.6 50, 150,300 8 220/302,522 
Cutler et al. 2009 41.25±12.1 150,300XR 6 126/168,294 
Young et al. 2010 42.5 300,600 8 192/326,518 
Calabrese et al.  2005 36.95±11.3 300,600 8 150/192,342 
Suppes et al. 2010 39±11.3 300XR 8 45/88,133 
Thase et al. 2006 37.7±10.7 300,600 8 137/169,306 
Langosch et al. 2008 45.4±11 465±167 52 6/16,22 
Liebowitz et al. 2010 45.4±11.2 176.6±95.5XR 52 132/255,387 
McIntyre et al. 2005 42.8 600 12 37/64,101 
Vieta et al. 2007 34.7 300,600 8 32/41,73 
Bortnick et al. 2010 43.3±10.5 162.2±96 XR 8 52/95,147 
     
Aripiprazole     
Sachs et al. 2006 40.4±10.5 27.7 3 69/68,137 
Vieta et al. 2005 42.6±11.9 15-30 12 76/99,175 
CN138-096* 39±11 17.6±8.3 8 71/115,186 
CN138-146* 41±12 15.5±7.5 8 75/112,187 
Keck et al. 2006 39±13.2 24.3 26 30/48,78 
Keck et al. 2003 40.5±12.7 27.9 3 59/71,130 
Kemp et al. 2010 38.2±12.8 15-30 26 27/51,78 
El Mallakh et al. 2010 40.3±11.5 15,30 3 128/139,267 
Young et al. 2009 40.5 22 12 72/95,167 
     
Ziprasidone     
Keck et al. 2003 39±10.6 130.1±34.5 3 73/58,131 
Keck et al. 2009 38.9±11 125.2±31.9 52 61/66,127 
Vieta et al. 2010 38.5±11.6 121.4 9 108/70,178 
Potkin et al. 2005 38.9±11.6 112 3 68/71,139 
     
Risperidone     
Muller-Siecheneder et al. 
1998 
41±12.2 8±1.45 6 25/37,62 
Smulevich et al. 2005 41.3±13.1 4.1±1.8 12 83/71,154 
Hirschfeld et al. 2004 38.1±11.9 4.1±1.4 3 71/63,134 
Khanna et al. 2005 34.7±12 5.6±1.2 3 99/47,146 
 
*Unpublished studies 
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Figure legends 
Figure 1: Flow Diagram Describing the Search Process for schizophrenia group 
 
Figure 2: Flow Diagram Describing the Search Process for affective disorder group 
 
Figure 3: Forest plot of the effect size estimates of cholesterol changes (mg/dl) in 
schizophrenia compared to bipolar disorder patients (p=0.000) by quetiapine 
treatment. CI: confidence interval, DT: diagnostic type, SCZ: schizophrenia 
patients, BP: bipolar disorder patients. 
 
Figure 4: Forest plot of the effect size estimates of LDL changes (mg/dl) in 
schizophrenia compared to bipolar disorder patients (p=0.000) by quetiapine 
treatment. CI: confidence interval, DT: diagnostic type, SCZ: schizophrenia 
patients, BP: bipolar disorder patients. 
 
Figure 5: Forest plot of the effect size estimates of akathisia incidence in 
schizophrenia compared to bipolar disorder patients (p=0.001) by 
aripiprazole treatment. CI: confidence interval, DT: diagnostic type, SCZ: 
schizophrenia patients, BP: bipolar disorder patients. 
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Figures 
1732 of records identified through database searching for
schizophrenia disorder
Number of records identified
through each database:
PubMed (566), PsycInFO (87),
EMBASE (1079)
791 reports retrieved for
more detailed evaluation
941 of records after
duplicates removed
744 of records excluded
with these reasons: type
of study, type of
publication, treatment
type, data not available
47 studies included in the
review: quetiapine (15),
ziprasidone (8), aripiprazole
(9), and risperidone (15)
 
Figure 1 
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1883 of records identified through database searching
for affective disorders
Number of records identified
through each database: PubMed
(1091), PsycINFO (76), EMBASE
(714) Clinicaltrials.gov website(2)
381 reports retrieved for more
detailed evaluation
1502 of records after
duplicates removed
348 of records excluded
with these reasons:
type of study, type of
publication, treatment
type, or not available data
33 studies included in the
review: quetiapine(16),
ziprasidone(4), aripiprazole(9),
and risperidone(4)
 
Figure 2 
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Group by
DT
Study name Statistics for each study Mean and 95% CI
Standard Lower Upper
Mean error limit limit
BP Bortnick et al. 2010 -2.600 3.232 -8.935 3.735
BP Culter et al. 2009 -4.250 1.560 -7.308 -1.192
BP Liebowitz et al. 2010 -5.220 1.552 -8.261 -2.179
BP McElroy et al. 2010 b -1.400 1.718 -4.768 1.968
BP Suppes et al. 2010 -3.510 3.036 -9.460 2.440
BP Weisler et al. 2009 0.360 1.133 -1.861 2.581
BP Young et al. 2010 -3.800 1.580 -6.896 -0.704
BP -2.765 0.938 -4.604 -0.927
SCZ Kahn et al. 2007 9.320 1.549 6.283 12.357
SCZ Lieberman et al. 2005 5.310 2.097 1.200 9.420
SCZ Lindermayer et al. 2008 11.080 1.702 7.745 14.415
SCZ Zhong et al. 2006 4.900 2.594 -0.184 9.984
SCZ 8.053 1.457 5.197 10.909
Overall 0.405 0.789 -1.141 1.951
-15.00 -7.50 0.00 7.50 15.00
Decreased
Cholestrol level
Increased
Cholestrol level
 
Figure 3 
 
 
 
 
  
Group by
DT
Study name Statistics for each study Mean and 95% CI
Standard Lower Upper
Mean error limit limit
BP Bortnick et al. 2010 -2.800 2.657 -8.008 2.408
BP Culter et al. 2009 -4.400 1.434 -7.210 -1.590
BP Liebowitz et al. 2010 -3.430 1.268 -5.916 -0.944
BP McElroy et al. 2010 b -2.800 1.517 -5.773 0.173
BP Suppes et al. 2010 -4.680 2.495 -9.570 0.210
BP Weisler et al. 2009 0.600 1.041 -1.440 2.640
BP Young et al. 2010 -3.600 1.407 -6.358 -0.842
BP -2.762 0.843 -4.415 -1.109
SCZ Kahn et al. 2007 5.670 1.272 3.177 8.163
SCZ Lindermayer et al. 2008 6.930 1.365 4.254 9.606
SCZ Peuskens et al. 2007 -0.390 2.911 -6.095 5.315
SCZ 5.008 1.566 1.938 8.078
Overall -1.016 0.743 -2.471 0.440
-15.00 -7.50 0.00 7.50 15.00
Decreased
LDL level
Increased
LDL level
 
Figure 4 
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Group by
DT
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper
rate limit limit
BP CN138-096 0.275 0.215 0.345
BP CN138-146 0.214 0.161 0.280
BP El Mallakh et al. 2010 0.124 0.090 0.169
BP Keck et al. 2003 0.110 0.066 0.178
BP Keck et al. 2006 0.065 0.027 0.147
BP Sachs et al. 2006 0.176 0.121 0.250
BP Vieta et al. 2005 0.114 0.075 0.171
BP Young et al. 2009 0.114 0.074 0.172
BP 0.146 0.107 0.197
SCZ Chrzanowski et al.2006 0.050 0.021 0.113
SCZ Cutler et al 2006 0.022 0.010 0.047
SCZ Kane et al. 2007 0.039 0.018 0.085
SCZ Kane et al. 2009 0.091 0.063 0.131
SCZ Kasper et al. 2003 0.129 0.108 0.153
SCZ Kerwin et al. 2007 0.014 0.005 0.037
SCZ McQuade et al. 2004 0.059 0.031 0.109
SCZ Pigott et al 2003 0.078 0.045 0.133
SCZ 0.054 0.032 0.088
Overall 0.108 0.083 0.141
-0.25 0.00 0.25 0.50
Less More
Akathisia Incidence
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This meta-analysis illuminates the relative side effect profiles of second-generation 
antipsychotics when prescribed for schizophrenia and affective disorder patients. The thesis 
covers the result of the first meta-analysis comparing metabolic and extrapyramidal side 
effects of second generation antipsychotics in the two groups of patients. It should be noted 
that in previous studies they have compared side effects of SGAs in patients with a 
particular disease (e.g., schizophrenia), while this thesis is focused on the difference of 
SGAs side effects in two psychiatric conditions.  
 In recent years metabolic syndrome and cardiovascular diseases have become a major 
concern in the patients with mental disorders who are treated with second-generation 
antipsychotics (Correll, 2007, De Hert et al., 2011b, Fleischhacker et al., 2008, Mitchell et 
al., 2012). Patients with schizophrenia have a twofold increased weight gain, diabetes and 
hypertension (De Hert et al., 2009). The aim in these two meta-analyses was to study the 
degree of sensitivity and tolerability of SGAs in AD and SCZ patients. 
 The results of this thesis suggest that schizophrenia patients may be more vulnerable to 
some SGAs-induced metabolic side effects. Based on the results, olanzapine and quetiapine 
are associated with more changes in metabolic parameters relative to other SGAs. These 
findings are consistent with other studies (Rummel-Kluge et al., 2010b, Simon et al., 2009). 
According to the findings of this thesis, olanzapine induces significantly more weight gain 
while quetiapine is associated with significantly higher LDL and total cholesterol mean 
change in schizophrenic patients compared to the AD group.   
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 In these meta-analyses, olanzapine induced significantly more weight gain in SCZ 
patients compared to the BP group, while with aripiprazole treatment, BP patients gained 
weight and SCZ patients lost weight. Olanzapine treatment increased blood glucose, 
cholesterol and triglycerides levels more in schizophrenic patients compared to BP patients. 
However, these changes were not significant between the two groups. By examining lipid 
profile of five SGAs between SCZ and BP patients, quetiapine treatment was associated 
with significant elevation in mean level of total cholesterol and LDL in the SCZ group 
compared to BP patients. In quetiapine treatment, SCZ patients gained more weight and 
showed more changes in triglycerides levels; however, these differences were not 
significant. In addition, for treatment with aripiprazole, risperidone and ziprasidone, no 
significant difference in metabolic side effects was found between SCZ and AD groups, but 
the SCZ group showed more elevation in these side effects.  
 The biological mechanism underlying different metabolic disturbances between SCZ 
and AD patients in SGAs treatment is not yet clear. Research groups have indicated 
different aspects of antipsychotic-induced metabolic disturbances in patients with chronic 
schizophrenia. This meta-analysis proposes that factors such as life style and disease 
phenotype may contribute to the observed greater susceptibility in the SCZ group. Genetic 
polymorphism may be an important risk factor influencing SGAs side effects between SCZ 
and AD patients. In addition to a genetic predisposition for metabolic syndromes among 
schizophrenic patients, lifestyle risk factors such as stress, poor diet, lack of exercise and 
smoking are more common in schizophrenic patients (Bai et al., 2011, Liou et al., 2012). 
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 The results on EPS symptoms defined that, in general, affective disorder patients tend 
to be more susceptible for movement disorders compared to schizophrenia patients with 
SGAs treatment, except for olanzapine treatment. It has been mentioned in other studies 
that patients with bipolar disorder are particularly sensitive to the development of EPS. On 
the one hand, previous studies have shown that treatment of bipolar disorder with first 
generation antipsychotics is associated with more incidence of EPS compared with 
treatment of schizophrenia (Nasrallah et al., 1988). On the other hand, results of Cavazzoni 
et al. (2006) showed that this greater vulnerability in AD groups is only present with first 
generation antipsychotics treatment and not for olanzapine treatment, which agrees with the 
findings of our work in regard to olanzapine. In addition, based on the results of the review 
by Gao et al. (2008) different tolerability in different psychiatric conditions are more likely 
due to the nature of illness of each individual psychiatric disorder. The exact reasons for 
different tolerability profiles for SGAs treatments among various psychiatric conditions are 
unclear. A reduced risk of EPS, especially akathisia, is important and can be expected to 
improve acceptability of treatment for patients with mental disorders.  
 In conclusion, side effects are important to consider for prescribers, because the 
efficacy of treatment may be reduced due to the presence of certain side effects. Therefore, 
better understanding of SGAs side effects, as far as possible, should be the primary aim of 
mental disorders treatment. The findings of this thesis, which have primarily focused on 
SGAs side effects in schizophrenia and bipolar disorder, provide new insight into the 
prescription of SGAs for different mental disorders and suggest the necessity of respecting 
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guidelines for screening and regular monitoring, especially for metabolic side effects in 
patients with severe mental illnesses.  
 Obviously, these findings need further investigation and the variable confounders are 
still to be clarified. In the presented meta-analyses the impact of previous exposure to 
antipsychotic treatments, race/ethnicity, severity of psychiatric illnesses and initial weight 
in both groups have not been examined, which may impact the generalizability of the 
findings. Thus, future works may include all these variable confounders in order to improve 
power and generalizability of this meta-analysis. In addition, it would also be useful to 
examine other side effects of SGAs such as sedation and somnolence, and compare them 
among different psychiatric conditions. Studies on safety profile of antipsychotics could 
help clinicians to better screen and monitor antipsychotic therapy for different mental 
disorders. Therefore, conducting studies on long-term safety of antipsychotic drugs should 
be considered a priority in psychopharmacology, as treatment with antipsychotics is often 
continued for a long period of time or even for the patients’ whole life.  
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